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Summary 
Systems Biology opens new frontiers in the studies of 
complex diseases such as Multiple Sclerosis (MS). The questions 
that couldn’t be addressed before due to lack of understanding 
and methodological base, such as the molecular mechanism of 
action of many drugs on the signaling pathways, were resolved 
using new Systems Biology vision of nature. Signaling pathways 
have dual biological and mathematical nature. Modern Systems 
Biology developed various methods to model signaling pathways 
and predict their behavior in different conditions.  
This dissertation is focused on some of the key molecular 
mechanisms of signal transduction in MS development and 
progression, which are important in order to explain the 
mechanism of action of the common MS drugs.  
My main hypotheses are based on the assumption that the 
most important art of the biological system are the connections 
between molecules rather than the molecules themselves (e.g. 
edges rather than nodes of the model graph). For example, the 
immune cell subtypes have different response to the external 
stimulus because the molecules regulate different activities of each 
other inside the cell rather than the components of the cells are 
different. Another examples of it are the kinetic changes driven by 
the changes in the translocation activity of the Stat1 protein. 
To prove my hypothesis, I developed two different 
mathematical models of IFNbeta pathway: Boolean and ordinary 
differential equations (ODE). The combination of two modeling 
approaches allowed us to look at the same pathway from two 
perspectives: in connection with other related pathways and as a 
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kinetic system. We identified oscillatory and damped oscillatory 
regimes in the IFNbeta signaling and the key sensitive parameters, 
which determine the switch of the regimes. Both model were 
validated experimentally and leaded to several predictions, which 
could be important for the development of new drugs or drug 
combination. For example, the bifurcation analysis of the kinetic 
model revealed the importance of the features of the nuclear 
translocation of the Stat1 protein for the correct functioning of the 
signaling pathway.  Sgk/Akt-Foxo3a is another pathway 
described, modeled and validated in my dissertation.  The nuclear 
translocation is a known key element of this system, but we 
focused on the on/off circuit mechanisms and the importance of 
the combination of different phosphorylation sites for signal 
transduction.  
The main outcomes of this work are: 
1. New models of IL6, IFNbeta and Akt/Sgk signaling 
pathways 
2. Predicted prevalence of translocation parameters 
over the phosphorylation rates on the IFNbeta pathway 
3. New method of the application of the Boolean model 
workflow to the clinical data 
As a conclusion, the Systems Biology is a powerful tool to 
predict new properties of the biological systems, which can be 
used in clinical practice, such as dynamical biomarkers or 
differential signal transduction. Thus, Systems biology provides a 
new approach to search for new treatments and biomarkers of 
autoimmune diseases.  
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Preface 
“Every object that biology studies is a system of systems”  
Francois Jacob, [1] 
The complexity of life and molecular processes underneath it 
is an exciting topic of research that shows the limitations of human 
brain that struggles to analyze the whole picture. That’s where the 
models and modern computational power come to hand and help 
to reach the higher level of understanding. The traditional 
biological approach of “dissection” of the object of interest and 
analyzing parts doesn’t provide new knowledge due to its obvious 
limitations. During the last several hundred years we learned a lot 
about the parts but still lack the knowledge about their functioning 
as a whole. Another traditional biological method is categorizing. 
The organisms, cells, molecules were categorized in different 
groups and subgroups (based on evolutional, phenotypic, genetic 
or other characteristics) and analyzed based on the differences and 
commonalities. 
Biologists and clinicians face more and more complicated 
challenges trying to answer modern medical questions. One of 
these topics is neuroimmunological disease, such as Multiple 
Sclerosis (MS).  The complex nature of MS combines genetic and 
environmental factors and the cause of the disease remains unclear 
[2]. Classical approaches are not able to capture the complexity of 
the interactions between different species involved in the 
development of the disease. For this reason, scientific community 
intends to develop and put in practice new methods of clinical 
research based on the interdisciplinary approach. For example, 
CombiMS consortium (http://www.combims.eu) aims to develop 
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new combination therapies for MS by combining 
phosphoproteomics studies with Systems Biology approach.  
 Systems Biology approach in molecular biology, although 
has its own limitation, is a new way to capture the sense of 
biological processes and analyze the interaction network in all its 
complexity. This dissertation aims to develop new methods and 
workflows to put together theoretical Systems biology and 
practical drug discovery.  
 This thesis is organized in several parts: general 
introduction, hypothesis, objectives, materials and methods, 
results and general discussion. It also includes references and 
supplementary data sections. The results are organized in several 
chapters representing separated but interconnected parts of my 
work: 
Chapter 1. Theoretical considerations on pathway dynamics in 
individual cells and cell populations 
Chapter 2. The Boolean model of IFNbeta signaling in human cell 
lines and a new approach to analyze clinical experimental data for the 
drug combinational therapy 
Chapter 3. Kinetic model of the IFN-beta signaling pathway in 
macrophages  
Chapter 4. Nuclear translocation as a modulator of the pathway 
kinetics. IFNbeta pathway example  
Chapter 5. AKT/SGK-Foxo pathway model 
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  3 
Introduction 
Mathematical modeling approaches in biomedicine  
Cell is a complex system with millions of elements working 
together as a whole. To understand the grade of complexity of the 
living organism, scientists developed a new field, Systems biology.  
The understanding of the idea that the organism is not just a 
sum of its elements is not new. It was known and acknowledged 
from the ancient times with Aristotle’s famous “the whole is 
something over and above its parts and not just the sum of them 
all’’.  Nevertheless, later on in the middle ages the reductionists 
approach was the mainstream paradigm of biological research. 
The prevalence of reductionism was favored by the development 
of physics and ideas of Rene Descartes in the 17th century. The 
prevalence of the reductionism was based on the idea that all 
complex systems can be explained by explaining their parts. The 
mechanistic biology was based on the reductionism theory. Its 
ultimate expression was expressed in the book “The mechanistic 
conception of life: biological essays” by Loeb Jacques (1912) [3].  
He summarized the paradigm of the mechanistic biology stating 
that the biological behavior was predetermined, forced, and 
identical between all individuals of a particular species. He 
concluded that the organisms were merely complex machines. In 
the beginning of the 20th century the holism concept was 
proposed to oppose the reductionism. Whole systems such as cells, 
tissues, organisms, and populations were proposed to have 
emergent properties. It was impossible reassemble the behavior of 
the whole system from the properties of the individual 
components. [4]. Even though the holism and reductionism 
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theories were generated in oppose to each other they can be used 
together. The two approaches answer different questions and can 
complement each other.  
 
Figure 1 A simplified hierarchical structure of a living system. The 
system is composed by the components with increasing complexity. On one 
edge of the pyramid are the physical entities and on the other their functional 
properties.  
The turning point in the history of Systems biology is the 
1950s. At this time the breakthrough book was published by Roger 
Williams [5]. Williams showed huge differences in physiological 
parameters and even organ size of normal healthy humans. Thus, 
it’s the systems balance that creates independent biochemical and 
physiological pattern and adopts and tolerates that variation. The 
tolerance and the resistance to variation is what differ living 
organism from mechanical machines.  The victory of systematic, 
holistic theory promoted various studies, which leaded to the 
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establishment of Systems theory. Systems theory states that two 
basic emerging features of any system are hierarchy and 
interconnectivity. 
The recognition of the hierarchical organizational properties 
of the system represented an important advance in understanding 
of the properties of biological phenomena [6].  A simplified 
example of hierarchy on living system is show on the fig. 1. Each 
level in the hierarchy is an emerging property of the complex 
interactions inside the lower level.  At the same time, each level is 
consisted of several subsystems each representing an emergent 
properties on its own, which can also be arranged in the 
hierarchical organization [7]. One of the main recognized features 
of the biological system is interconnectivity. Interconnectivity is a 
more complicated concept. It includes different connections 
between systems, networks and individual components (fig.2). 
Interconnectivity between different layers of the hierarchy was 
first recognized in the late 60s. Polanyi (1968) first clarified the 
relationship between levels in a hierarchy. He showed that 
adjacent levels mutually constrain but do not determine each other 
and emphasized that the upper level harnesses the constituents of 
the lower level to carry out behaviors that they would not perform 
on their own [8].  
At the same time scientific community identified numerous 
example pointing that the layers of the hierarchy are highly 
connected in a more complex system rather than working as 
independent blocks. This recognition led to the formulation of the 
general systems theory by Von Bertalanffy [9]. 
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Figure 2 The interconnection between different layers of cellular system. This 
figure represents only the connections between different layers of signaling. 
The interconnections create increasing complexity systems of intersections 
and relationships between subsystems in the same layer and between 
different layers of the hierarchical system.  
Bertalanffy argued that all systems shared the similar 
properties and were composed of interconnected components; 
therefore they should share similarities in detailed structure and 
control design. Nowadays the theory received strong evidence 
based on the studies of mathematicians, physicists, biologists, and 
physiologists. It’s believed that hubs and connectors represent a 
common stable structure of a real system. Hubs are the central 
components, which are linked to many other nodes in the system, 
while connectors are connected to a few other nodes (fig. 3) [10].  
In the 20th century Systems biology evolved from molecular 
biology in two parallel historical roots [11].  On one side the most 
acknowledged root is based on the technological breakthroughs in 
the genomics and other “omics” disciplines. 
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Figure 3 Basic graph models representing different combinations of 
both modular and hub characteristics from [12]. Most real Systems are both 
modular and contain hubs (central nodes), e.g. D or F graphs of the figure.  
While new technologies increased exponentially the amount 
of biological information, new methods were needed to 
comprehend and analyze them. This root led to the big networks 
of connections and was more “statistical” in character. These 
networks can explain and describe a system as whole but lack 
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dynamical dimension.  
The other root of the historical development of Systems 
biology is much less known. It consisted of the effort, which was 
constantly focused on the formal analysis of new functional states 
that arise when multiple molecules interact simultaneously. These 
approaches were historically called nonequilibrium dynamics and 
may be seen as an ancestor of the modern Systems biology. The 
main characteristic of this discipline raised from this root was the 
focus on the discovery of general principles rather than 
descriptions. The nonequilibrium dynamics was interested in such 
traditionally physics concepts as oscillators, chaos, noise, steady 
state and symmetry of the systems.  
Until the end of the 20th century the dynamical and theoretical 
biology was highly rejected by the biological community as 
“unuseful” for answering “real” biological questions. The 
beginning of the 21st century marked the phenomena of the 
convergence of the two paths in to one mainstream Systems 
biology approach. The reductionism is now giving its way to the 
holistic tendency in biology under the pressure of growing amount 
of big data. As a result the convergent Systems biology unites the 
dynamical methods and high-throughput statistical models 
creating impressive mathematical constructs to explain 
increasingly complex systems. For example in the work of Karr et 
al. the whole-cell model predicts the behavior of the entire simple 
organism [13].  
The main difference between Systems biology and traditional 
Molecular biology is the focus on the connections rather than on 
the molecules forming them. Systems biology takes the cell as a 
  9 
complex interacting system and analyzes the connections and 
common patterns of this system. What seemed to be the universe 
of different structures and patterns at the end was shown to be the 
combination of several commonly repeated circuits, which lead to 
several classes of behavior responses [14].  Evolutionary chosen 
circuits are sharing similar characteristics: resistance to noise and 
perturbations, stabilizing power together with sensitivity to the 
external factors. These features are critical for the survival of the 
living organism and its functional stability in the complex 
environment. Natural selection selected the best evolutionary 
adapted to the environment circuits, which are both functional and 
stable. These circuits are responsible for all the variety of responses 
and behaviors of the cell, which includes, among others, 
oscillatory and overdamned oscillatory behaviors, exponential and 
sigmoid curves, pulse generators, bi-stable motifs and more 
complex combinations of different patterns and circuits.  
Most common patterns in signaling 
The building blocks of complex networks are called network 
motifs. In other words network motifs are the patterns that appear 
significantly more frequently in real networks than in randomized 
networks [15]. The network motifs are persistent in the regulatory 
networks. It was speculated that this persistence is a result of 
evolution and the motifs are derived from the constant selective 
pressure that means their structures provide advantages in natural 
selection.  Nevertheless, many studies suggest that the the 
common subgraphs within network may be selected by nature a 
posteriori to their appearance and the abundance of motifs is a 
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byproduct of the network construction process [16]. In any case, 
motifs are useful tools to construct biological networks.  
 There are several common network motifs, which are 
also present in the models described in this dissertation:  
1. Single input and regulatory chain  
2. Feed-forward motif 
3. Positive and negative feedback loops 
The graphical representation of different motifs is shown on 
fig. 4.  
 
Figure 4 Most common network motifs. A – regulatory chain (left) and 
single input (right); B – feed-forward motif; C – Feedback loops: positive (left) 
and negative (right). 
Different motifs produce different dynamics of the system. 
For example, negative feedback loop leads to oscillatory behavior 
of the system. Oscillators are very common in signaling systems 
and commonly appear when the product of some transcription 
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factor (TF) activity inhibits the activation of this TF thus producing 
a negative feedback loop (fig. 5). 
 
Figure 5 Multi-component negative-feedback oscillator. A. Negative 
feedback between mRNA and protein, as described by kinetic equations in 
the text. B. Representative solutions (dashed curves) of equations in the text, 
for parameter values: p = 2, Km/Kd = 1, S/Kd = 1, k = k = 0.1 min
–1, k = k E /K = 1 
min–1. Notice that every trajectory spirals into the  stable steady state located at 
the grey circle. C. The negative-feedback loop, taking into account transport 
of macromolecules between the nucleus and the cytoplasm. D. Sustained 
oscillations for the four-component loop in panel. From [17] 
 The negative feedback showed on the fig. 5 can be 
represented by the following equations [17]: 
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where X and Y are mRNA and protein concentrations, kdx and k sy for 
degradation of mRNA and synthesis of proteins, the term 
 
is the rate of the RNA synthesis and the term 
 
is the term for protein degradation.  
So with only 2 (or even one with explicit time delay) 
equations we may reproduce the oscillatory behavior that we see 
so frequently in the biological systems. 
Bistability is a situation in which two possible steady states are 
both stable. In general, these correspond to a "low activity" state 
and a "high activity" state. There are several patterns that may 
produce bistability (fig. 6). Each of them produces bistability only 
in the certain range of parameters, e.g. it’s not mandatory for the 
systems containing mutual activation or mutual inhibition circuits 
to lead to bistability.  
 
Figure 6 The circuits, which may produce bistability: mutual activation (on 
the left) and mutual inhibition (on the right). From [18] 


  
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In the bistable system the multiple steady states are possible 
and the initial conditions determine which steady state is reached 
[19] The examples of bistable systems include lac operon in E. coli 
[20] and MAPK cascade [21]. In our model of IFNbeta we also 
found bistability and analyzed the bifurcation (see chapter 4 of the 
results section).  
Different methods of modeling in Systems biology 
 
Figure 7 Data sets can dictate the computational approaches used in 
systems biology. (Left) Omics technologies generate extremely large data sets 
that can be analyzed and organized into networks by using statistical 
modeling techniques. This strategy can be considered “top-down” modeling. 
(Right) When high-quality data are available, smaller-scale systems can be 
represented by dynamical models, and simulations with these models can 
generate quantitative predictions of system behavior. This strategy is 
sometimes called “bottom-up” modeling. Both approaches are important in 
systems biology, and a few cutting-edge studies combine the positive aspects 
of both. From [22] 
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There are two basic approaches in Systems Biology, which 
rose from the two historical paths of the scientific field 
development we discussed above.  The first one evolved from 
statistical methods and is called “Top down” and the other one, 
dynamical, is called “Bottom up” (fig. 7) (from Coursera 
“Dynamical modeling methods for Systems biology” course by 
Eric Sobie).  
Models as logic systems 
 “Top down” method commonly involves following steps: 
1) Begin with data set (often very large scale) 
2) Use statistical methods to find patterns in the data. 
3) Generate predictions based on the structure within 
the data 
The amount of data and the size of the networks obligate the 
researchers working in this area of Systems biology to propose the 
simplified approaches to assess large-scale data. One of the 
approaches is to design logic, static or semi-static models, which 
are qualitative or limited in terms of quantifying time-dependent 
changes. One of the common methods is logic modeling which 
treats the connections between molecules as logic variables [23]. 
The logic modeling consists of building a Boolean network where 
nodes are connected with binary edges (the values on the edges 
can be only ON or OFF). The nodes can be AND or OR logic 
functions. There are many deviations and add-ons to make this 
simple models more flexible, include time or stochastic inputs [24].  
In this dissertation we used the software designed by Dr Saez 
group in EBI and called CellNoptR [25]. The R package is available 
in Bioconductor and depends on RBGL and graph packages 
(http://bioconductor.org/packages/2.10/bioc/html/CellNOptR.
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html). CellNoptR package does optimization of Boolean logic 
networks of signaling pathways based on a previous knowledge 
network (PKN) and a set of data upon perturbation of the nodes in 
the network. The detailed information on the usage of the package 
can be found in the package manual and the methods section of 
this dissertation.  
Models as dynamical systems 
 “Bottom up” approach is based on the following sequence 
of steps: 
1) Begin with hypothesis of biological mechanism. 
2) Write down equations describing how components 
interact. 
3) Run simulations to generate predictions. 
The classical method to model dynamical biological system is 
by set of ordinary differential equations (ODE). ODEs describe the 
model as variable changes in time: 
 
where y – is a variable and p – a vector of parameters. 
Depending on the number of variables the system may have 
multiple dimensions. Each new dimension leads to increasing 
number of possible dynamical outcomes of the system.  While one-
dimensional reactions are able to produce only steady state 
dynamics, the three-dimensional systems produce several different 
kind of dynamics, e. g. steady state, limit cycles and chaos [26]. 
Many signaling pathway events are explained by using a 
modified Hill function. Hill function is typically used in 
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biochemistry to describe ligand-binging reactions based on 
Michaelis-Menten dynamics: 
 
Hill function describes many real gene input functions, which 
are usually monotonic S-shaped functions. The Hill function for an 
activator is a S-shape curve that rises from zero and approaches a 
maximum saturated level: 
 
where K is an activation coefficient, β is a maximum 
expression level and n is a Hill coefficient, which corresponds to 
the steepness of the function [14].  
One of the main challenges in ODE modeling approach is the 
number of parameters. The parameters should be assigned or 
fitted to achieve the desired simulation outcome. There are 
different ways to fit the parameters: 
1. Manual fit. This way the parameters are obtained from the 
experimental papers and adopted to the model [27]; 
2. Automatic fit. There are various algorithms and methods to 
automatically fit the parameters to the data [28–31]. Most of 
them are based on the exploration of the multi-dimensional 
parameter space to find the combination of parameters, 
which corresponds to the maximum model fit to the data (fig. 
8); We used manual fitting and literature search to obtain 
parameters for IFNbeta ODE model (see results).  
3. Exploration of the parameter space. The other approach to 
solve the parameter problem in the dynamic systems is the 
exploration of the all possible qualitative outcomes of the big 


 

  
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range of parameters. The workflow we use here to explore 
the parameter space of Foxo3a pathway models was 
developed by Gomez-Cabrero et al. [32]. 
 
 
Figure 8 The 2-dimensional parameter space vs model fitness to the data. 
Most of the algorithms search for the combination of parameters to maximize 
model fitness.  
Populations of cells versus single-cell modeling 
Most experimental data are coming from the analysis of cell 
populations (Western blot, RT-PCR, Elisa, Luminex and other 
methods are working with cell lysates).  Population level 
measurements may not only average out the variation in the 
response and mask heterogeneity, but also hide important 
biological phenomena (fig. 9).  
Nowadays the advanced technologies allow several 
techniques to measure the protein concentrations and 
phosphorylation on a single-cell level. These methods include, 
among others, Flow cytometry and derived from it flow imaging 
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ImageStreamX (Amnis co.) system. Flow cytometry measure the 
fluorescence signal from each individual cell on a high-throughput 
manner [33]. The standard analysis of flow cytometry data 
averages the signal from the single-cell measurements, but we can 
use the raw data to verify the behavior of the pStat3 on a single-
cell level.  
 
Figure 9 Examples of single cell behaviors that produce the same average 
population behavior. Individual cells are shown as circles with each cell’s 
signaling activity denoted by its color; black denotes 100% signaling and 
white denotes 0% signaling. The population average for each panel is 50%. In 
panel A, each cell signals at 50%. In panel B, half of the cells are in the 100% 
state and half of the cells are in the 0% state. In panel C, cells are as in panel 
B, but individual cells may switch states in time without affecting the 
population average. The switching may occur stochastically, or result from 
  19 
oscillatory signaling activity whose phase and frequency vary from cell to 
cell. In panel D, cell signaling is distributed between 0 and 100%. In panel E, 
signaling within a cell is spatially heterogeneous such that the average 
signaling within each cell is 50%. From [34] 
Classical ODE modeling is based on assumption that there 
are enough of molecules of the modeled species to justify the 
usage of the concept of concentrations as a smooth function. This 
assumption is often inaccurate for signaling in single cells [34].  
Signaling within individual cells often behaves probabilistically 
and requires stochastic simulations. The formal way to represent a 
stochastic system is commonly used chemical master equation 
which represents the probability that the system contains a certain 
number of molecules evolves over time [35]. 
Signaling pathways involved in Multiple Sclerosis 
Multiple Sclerosis (MS) is an autoimmune disease affecting 
more than 2 million people worldwide. MS is an autoimmune 
inflammatory disease of the central nervous system (CNS). MS is 
chronic and the progression depends significantly on the 
individual, but it nearly always culminates in the increasing 
disability. MS normally begins in the young adulthood and is 
driven by inflammatory attacks against myelin protein, which 
covers the axons of the neurons. The zones of the brain affected by 
demyelination process are visualized on the MRI scans as plaques 
[36]. The symptoms vary depending on the zone of a new immune 
attack.  
There are several different types of the MS: relapsing-
remitting (the most common), primary progressive, secondary 
progressive and progressive-relapsing forms (fig.  10). 
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Figure 10 Different types of MS produce different clinical course.   
All forms of MS are characterized by abnormal immune 
activity both in the blood and in the brain. The T cells are the main 
drivers of the immune attack on the myelin. Normally the immune 
attack occurs during a short period called relapse followed by a 
longer period of remission and partial recovery due to the 
reparation ability of the brain driven mainly by glial cells. The 
neuroinflammatory period of the disease is often followed by 
increasing neurodegenaration. Neurodegenaration is characterized 
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by axonal damage and brain volume reduction and no partial 
recovery (fig. 11).  
 
Figure 11 The inflammatory phase of multiple sclerosis. T cells, B cells 
and antigen-presenting cells (APCs), including macrophages, enter the central 
nervous system (CNS), where they secrete certain chemicals known as 
cytokines that damage the oligodendroglial cells. These cells manufacture the 
myelin that insulates the neuronal axon. The injured myelin cannot conduct 
electrical impulses normally, just as a tear in the insulation of a wire leads to 
a short circuit [37] 
The cause of MS is unknown but it’s believed that both 
genetic and environmental factors are involved. There are more 
than 100 SNPs recognized as associated with MS by recent 
genome-wide association studies [38]. The environmental factors 
include, among others, infections (associated with EBV, HHV6, 
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MSRV), vitamin D and sun exposition, smoking, diet and western 
style of life.  
The treatment options of MS are limited to disease-modifying 
therapies primary targeting the inflammatory part of the disease, 
but not neurodegenaration.  Immunomodulatory drugs currently 
used in the treatment of MS are divided in first line therapy 
(Interferon beta (IFN-beta), glatiramer acetate (GA)) and second 
line therapy (natalizumab, fingolimod or mitoxantrone).
There are several key signaling pathways, which are crucial 
either in disease progression or treatment efficacy. The list of 
known MS-related pathways include IFNbeta signaling, S1P 
signaling, TLR, different interleukin-modulated pathways, vitamin 
D signaling, PI3K signaling, TrkA and TrkB and others.   
In this dissertation we are focused on the several of these 
pathways: IL6 signaling pathway, IFNbeta signaling pathway and 
PI3K-Foxo pathway.  
IL6 signaling 
IL-6 is a pleiotropic cytokine with important role in immune 
regulation, hematopoiesis, inflammation and oncogenesis. IL-6-
type cytokines exert their action via the signal transducer gp130 
that associates with IL6R in a cooperative manner to form a 
hexameric signal transducing complex, capable of activating the 
down stream mediators of this signaling pathway. This 
mechanism of signal transduction is shared by other members of 
the IL-6 type cytokines like IL-11, leukaemia inhibitory factor, 
oncostatin M, ciliary neurotrophic factor and cardiotrophin-1 that 
use gp130 as a common subunit of the signal transducing complex 
[39]. IL-6 stimulation leads to the activation of Jak/Stat pathway 
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[40] (fig. 12) . Stat3 protein is phosphorylated and is able to form 
homodimers after activation leading to their its localization and 
subsequent regulation of transcription of respective target genes.  
 
Figure 12 The main events of IL6 signaling and pathway self-regulation. 
Schematic representation of the circuit. Cytokines bind their membrane 
receptors, causing a cascade of phosphorylation reactions that triggers Stat 
activation. Active Stats upregulated the transcription of the repressors SOCS, 
which inhibit Stat phosphorylation 
SHP-2 is one of the ubiquitous tyrosine phosphatases and IL-6 
stimulation leads to the SHP2-dependent activation of MAPKs, it 
also links the Grb2–SOS complex and Gab1 to gp130. 
Phosphorylated Gab1 acts as an adapter and is involved in the 
indirect association of SHP-2 and PI-3 kinase. Downstream 
activation of Vav1, Rac-1 and MAP2K4 is necessary for the IL-6-
mediated Stat3 phosphorylation and transactivation to accomplish 
its effects. PTPN11 and SOCS3 exert inhibitory function and thus 
lead to down regulation of the signaling cascade. 
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IFNbeta signaling  
One of the most studied prototypical signaling pathways in 
MS is type I interferon pathway. This is a pathway driven by Jak-
Stat signaling.  It is able to integrate environmental information 
related with infection (virus and bacteria) through the ligation 
with more than 15 different IFNα and one IFNβ. The canonical 
type I interferon (IFN) pathway involves different signaling 
cascades, one of which is the Jak/Stat pathway. This pathway is 
composed by several steps, which include receptor binding, 
transformation of the latent transcription factor (a protein of the 
Stat family) into its active form by phosphorylation, nuclear 
migration of the transcription factor (TF), binding of the TF to 
target promoters, and expression of their corresponding genes 
[41]. Type I IFNs bind to IFNAR1 receptors, phosphorylation of 
Jak1 and TYK2 proteins transmit the signal downstream, 
phosphorylation of Stat1 and Stat2 proteins allows to form the 
ISGF3 complex (pStat1-pStat2-IRF9) which binds to the ISRE 
binding sites in the nucleus. Previous studies have shown that 
phosphorylated Stat1 forms other TF complexes in response to 
type II interferons, the most important of which is a Stat1-Stat1 
homodimer, known as GAF, that binds to IFN Gamma-activated 
sequence (GAS) elements [42]. 
It was shown that at the same time that the ISGF3 complex is 
formed due to the stimulation, there is also formation of other 
transcription factors containing activated Stat1 [43]. The main one 
of them is GAF (Stat1-Stat1 homodimer), the primer complex for 
the type II IFN pathway (fig. 13). There are different activator and 
inhibitor molecules, which regulate the Stat1 tyrosine 
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phosphorylation. One of the most important inhibitors of Stat1 
phosphorylation is Socs1. Its expression is regulated by GAF 
transcription factor (pStat1-pStat1) binding to GAS elements, 
which are presented in Socs1 promoter (fig. 13).  
Dynamical models of IFN induction of the Jak/Stat signaling 
pathway based on nonlinear ordinary differential equations, have 
been previously used to study the effect of IFN pre-treatment on 
the response of the immune system to virus infection [44, 45] and 
the robustness of the pathway to noise and parameter fluctuations 
[46], among other problems. Previous studies suggested that a 
combination of positive and negative feedback loops, together 
with the eventual degradation of the IFN signal in the medium, 
leads to a transient oscillatory response in several components of 
the pathway.  
Type I interferons, such as interferon alfa and beta, are 
cytokines that represent a first-line endogenous defense 
mechanism in response to viruses and bacterial infections, and are 
secreted by many cell types (e.g. lymphocytes, macrophages and 
endothelial cells). Because type I interferons play a key role in both 
innate and adaptive immunity, they are frequently used as a 
therapy in Multiple Sclerosis (MS) treatment. 
Stat1 is a protein of the Signal Transducer and Activator of 
Transcription (Stat) protein family.  Stat1, as other Stats of the 
protein family, is activated by cytokines binging to the appropriate 
receptor, mainly IFNAR1 or IFNGR. The activation is produced 
mainly by tyrosine phosphorylation. The phosphorylation of Stat1 
causes immediate dimerization of the protein in its SH2 domain. 
[47] Stats tend to form both homo- and heterodimers.  In case of 
  26 
Stat1 the main dimers are Stat1-Stat1 and Stat1-Stat2, which are 
produced in different amounts by activation of different receptors. 
The engagement to form homo- and heterodimers are regulated by 
the balance in the concentrations of external inputs (cytokines). On 
the other hand, there are numerous regulators of Stats activity 
both inside and outside the nucleus, including Socs1 and Irf1 [43]. 
 
 
Figure 13 The canonical type I and type II IFN signaling pathways. The 
plot represents the canonical IFN pathways and the cross-talk between them, 
including the different pStat dimers formed after stimulation. [48] 
The target genes of the IFN-beta pathway can be divided into 
three categories according to the type of activating transcription 
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factor: 1) the ISGF3 complex activates genes containing an ISRE 
binding site in their promoter (e.g. ISG15, Mx1, OAS1, IRF7). These 
genes are known to be upregulated in T-cell populations of 
immune cells upon IFN-beta stimulation or virus-induced IFN-
beta production. 2) The GAF complex activates genes containing a 
GAS binding site in their promoter, such as Socs1 and IRF1. Early 
studies found Socs1 and IRF1 to be up-regulated mainly upon 
IFN-gamma induction, but recent work has shown their 
importance in IFN-beta pathway regulation in macrophages [49, 
50]. 3) A third class of Stat protein complexes activates other 
canonical pathways that exhibit crosstalk with the Jak/Stat 
pathway (such as PI3K, NFkB, MAPK) [51]. Recently it was shown 
that different immune cell subtypes respond differently to IFN-
beta induction through activation of these different types of genes 
[52]. 
Different proteins regulate Stat1 phosphorylation. 
Importantly, a negative feedback loop upon Stat1 activation 
coexists with a positive feedback mechanism. First, the 
phosphorylation of Stat1 is inhibited by its inhibitor Socs1 [53]. The 
Socs1 protein then inhibits Stat1 phosphorylation at the kinase 
level. Besides this negative loop based on Socs1, Stat1 is a subject 
to positive regulation via the TF IRF1, whose transcription is 
induced by activated Stat1. IRF1 promotes the expression of the 
Stat1 gene at the transcriptional level. Given the existence of these 
multiple feedback loops, a mathematical modeling of the system 
would help provide an understanding of the response to type I 
IFN-beta.  
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Sgk/Akt-Foxo3a signaling 
Another well-known pathway critical for the trophic factor 
signaling is Pi3K. PI3K-Akt pathway is a key signaling pathway in 
apoptosis that plays an important role in longevity and cancer. It is 
activated by growth factors such as Insulin Growth Factor (IGF1). 
IGF1 binds to the external domain of the Receptors of tyrosine 
kinase (RTK). The phosphorylation of the inner domain of the 
receptor leads to the binding of PI3K. Activated PI3K binds to PIP2 
membrane phospholipid transforming it to the activated PIP3 
form. PIP3 activates Pgk1 signaling kinase, which activates Akt by 
phosphorylation. pAkt triggers many different cellular processes 
promoting cell growth and preventing cell death. The main 
mechanism of PI3K-Akt signaling is an activation of protein 
synthesis and translation by mTOR. The other mechanism is the 
inhibition of Foxo3 apoptotic activity by phosphorylation. 
While the well-studies kinase acting downstream of PI3K is 
Akt, there are other kinases involved in the regulation of 
downstream TFs. One of the families of these kinases is the serum- 
and glucocorticoid-inducible protein kinase (Sgk). Sgk proteins are 
phosphorylated by PI3K-dependent mechanism, but not through 
PIP3 phospholipid. SGKs are serine/threonine kinases that are 
related to Akt. In common with Akt, these proteins are activated by 
the PI3K pathway and translocate to the nucleus in cells stimulated 
with survival factors. SGK1 phosphorylates FoxO3a at the same 
sites as those phosphorylated by Akt, likewise leading to the 
cytoplasmic localization and inhibition of FoxO3a. However, SGK1 
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preferentially phosphorylates serine 319 whereas Akt prefers serine 
256 [54].  
The Foxo (Forkhead Box, type O) family of transcription 
factors (TFs) cause changes in gene expression to implement a 
cellular stress response program, and an increase in their activity 
leads to the genetic interventions that extend lifespan in model 
organisms. Foxo are conserved in all animals from worm to 
human. There are four closely related Foxo proteins in mammals, 
Foxo1 (FKHR), Foxo3 (FKHRL1; Foxo3A), Foxo4 and Foxo6. All 
Foxo proteins are widely expressed in different tissues, but Foxo3 
is especially highly expressed in the brain. Foxo factors contribute 
to the regulation of various processes such as cell cycle 
progression, cell size determination, cell death, cell differentiation, 
resistance to stress, and energetic metabolism. [55] 
Phosphorylation of Foxo proteins in response to growth factors 
such as IGF-I, erythropoietin, epidermal growth factor or nerve 
growth factor causes exclusion from the nucleus [56] For many 
growth factor-activated protein kinases, the specific 
phosphorylation sites are known. These include Akt and serum 
and glucocorticoid inducible kinase (Sgk), which are activated 
mainly through the PI3K pathway [57, 58]. Phosphorylation of 
Foxos in response to oxidative stress involves JNK and results in 
Foxo import in the nucleus. Foxo residues targeted by these 
kinases are different from those targeted by growth factor-
regulated kinases [59–61]. The effect of oxidative stress appears to 
prevail on the effect of growth factors [62]. Probably, a more 
important determinant of Foxo protein expression is its rate of 
degradation [63].  
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Figure 14 Some of Foxo3 inhibition mechanism from [64]. Note the 
alternative IGF1 activator - Sgk 
New implication of Akt-Foxo3 signaling in neuronal and 
behavior response [65, 66] opens a new field of possible drug 
targeting of Foxo TF for autoimmune and neurological diseases.  
The PI3K-Akt pathway is critical for growth factors signaling 
to promote cell survival through phosphorylation of Foxo3. In this 
pathway, nuclear translocation of Foxo3 after phosphorylation is 
the key step for modulating gene expression pattern (fig. 14). This 
pathway can be impaired in patients with neurodegenerative 
diseases leading to neuronal loss. Moreover, neuroprotective 
therapies targeting this pathway are promising therapeutic 
approaches for brain diseases. For this reason, understanding the 
dynamics and bottlenecks of this pathway will be useful for 
monitoring and predicting the response to these drugs. A previous 
target genes
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mathematical model on dynamic features of Foxo TF was 
described before [67].  The model is focused on the post-translation 
modifications and their implication in the Foxo fate (fig. 15).  
 
Figure 15 Fundamental reaction types of Foxo translocation (from [67])  
The regulation pattern of Foxo3a is highly conserved 
through all vertebrates. The pathway is regulated by an inhibitor 
loop Pten--|PI3K (fig. 16). This loop may lead to the alternative 
behavior of the system that is important for our kinetic model. 
Foxo3a TF directly regulates Pten gene expression. Therefore, the 
inhibition of Fioxo3a leads to activation of Pten and inhibition of 
PI3K phosphorylation. This work can be helpful in order to 
identify some of the important parameters for Sgk/Akt-Foxo3a 
signaling model. 
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Table 1 The list of Foxo target genes from [68] 
 
 
 
Target
Up- or
downregulation FOXO Pathway References
Cyclin D  FOXO3, FOXO4 Cell cycle 84
Cyclin G2 þ FOXO1, FOXO3, FOXO4 Cell cycle 17, 58
P130 þ FOXO1, FOXO3, FOXO4 Cell cycle 17, 54
P15 þ FOXO1, FOXO3 Cell cycle 47
P19 þ FOXO1, FOXO3 Cell cycle 47
P21 þ FOXO1,FOXO3,FOXO4 Cell cycle 65, 88
P27 þ FOXO1, FOXO3, FOXO4 Cell cycle 24, 61, 92
Plk þ FOXO1 Cell cycle 106
Manganese superoxide dismutase þ FOXO3 Stress resistance 53
catalase þ FOXO3 Stress resistance 66
Peroxiredoxin III þ FOXO3 Stress resistance 18
Sterol carrier protein þ FOXO3 Stress resistance 21
Gadd45 þ FOXO3, FOXO4 DNA repair 30, 100
Bim þ FOXO3 Apoptosis 23, 33
Fasl þ FOXO1, FOXO3 Apoptosis 13, 19
Tumor necrosis factor
receptor-associated death domain
þ FOXO1 Apoptosis 81
Tumor necrosis factor-related
apoptosis inducing ligand
þ FOXO1, FOXO3 Apoptosis 63
p53 upregulated modulator
of apoptosis
þ FOXO3 Apoptosis 105
Bcl 6 þ FOXO3, FOXO4 Apoptosis 28, 98
PTEN-induced kinase 1 þ FOXO3 Apoptosis 62
Glucose-6-phosphatase þ FOXO1, FOXO3 Metabolism 69, 78
Phosphoenolpyruvate carboxykinase þ FOXO1 Metabolism 86
PGC1 þ FOXO1 Metabolism 20
adiponectin þ FOXO1 Metabolism 79
Agouti-related protein þ FOXO1 Metabolism 49, 51
proopiomelanocortin  FOXO1 Metabolism 49, 51
neuropeptide Y þ FOXO1 Metabolism 49
Apoliprotein C-III þ FOXO1 Metabolism 2
Pdx1  FOXO1 Metabolism 52
B-cell translocation gene 1 þ FOXO3 Differentiation 5
Id1  FOXO3 Differentiation 10
Atrogin-1 þ FOXO3 Muscle atrophy 83
Bnip3 þ FOXO3 Muscle atrophy 57, 107
LC3 þ FOXO3 Muscle atrophy 57, 107
Garabl12 þ FOXO3 Muscle atrophy 107
Interleukin 7R þ FOXO1 Inﬂammation 70
C=EBPb þ FOXO1 Inﬂammation 43
Interleukin 1b þ FOXO1 Inﬂammation 94
4E binding protein 1 þ FOXO1, FOXO3 Insulin signaling 76
InsR þ FOXO1 Insulin signaling 77
trible 3  FOXO1 Signaling 59
Caveolin-1 þ FOXO1, FOXO3, FOXO4 Signaling 82, 102
Protein phosphatase 2A  FOXO1 Signaling 67
FOXO1 þ FOXO1, FOXO3 Signaling 27
FOXO3 þ FOXO1, FOXO3 Signaling 27
P110a þ FOXO3 Signaling 42
Collagenase þ FOXO3 Extracellular matrix
degradation
60
Matrix metalloproteinase 9 þ FOXO4 Extracellular matrix
degradation
55
Mxi1 þ FOXO3 Tumor suppression 22
Estrogen receptora þ FOXO3 Tumor suppression 35
Myostatin þ FOXO1 Differentiation 1
Endothelial nitric oxide synthase  FOXO1, FOXO3 Vessel formation 75
Multidrug resistance protein 1 þ FOXO1 Drug resistance 36
CBP=p300 interacting transactivator 2 þ FOXO3 Angiogenesis 6
Listed are transcriptional targets that have been reported to be directly regulated by FOXO1, FOXO3, or FOXO4. FOXO target genes are
grouped by cellular function. The effect of FOXO activation on the expression level: upregulation and downregulation are indicated
by andþ , respectively.
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Figure 16 Regulation of Foxos is conserved between Caenorhabditis elegans, 
Drosophila melanogaster, and mammals. Activation of the insulin receptor 
(DAF-2) activates PI3K (AGE-1) resulting in the formation of PIP3. These 
phosphorylated lipids form docking sites for PDK1 and PKB (AKT) resulting 
in their activation. PKB phosphorylates and inhibits Foxo transcription 
factors. While C. elegans and D. melanogaster have a single Foxo isoform, in 
mammals three distinct Foxos are regulated by PKB: Foxo1, Foxo3, and Foxo4. 
From [69]) 
Systems biology approaches in the development of new 
biomarkers and drug combinations for autoimmune diseases 
Extracellular molecules, such as cytokines, play a crucial role 
in signal transduction. Cytokines mechanism of action is a 
complicated network of closely connected intracellular signaling 
pathways. In general, binding of cytokines to the cell receptors 
forces the activation of different pathways to provide a systematic 
response. Although significant knowledge has been acquired in 
the last decades regarding the molecular components in the 
signaling pathways, how the cell computes information is not well 
understood. For this reason, the combination of biochemistry, 
molecular biology and systems biology approaches may provide 
new insights about this critical cell process. 
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Systems biology is achieving an outstanding level of 
understanding of complex processes. A hot topic in clinical 
research actively using Systems biology approach is drug 
combinations discovery for complex diseases such as type II 
diabetes [70], breast cancer [71], MS (CombiMS FP7 project) and 
others. There is a number of new methods and tools to identify 
effective drug combinations based on the big data networks (for 
example, [71, 72]). 
Clinical studies call for interdisciplinary efforts to confront 
the challenges of the autoimmune and neurological disorders such 
as MS [73]. With the increasing amount of produced data and little 
progress in the therapy of these diseases the Systems Biology 
approaches are the key to break the wall of misunderstanding of 
the deep mechanisms of the pathogenesis of MS.    
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Hypothesis 
The main players of the biological systems are the 
interactions between the molecules rather than the molecules 
themselves. It’s rather connections then nodes, which determine 
the behavior of the whole cell. From this perspective I’m going to 
determine several hypothesis examining different layers of 
hierarchical living system:  population of cells, entire cell and 
particular signaling pathway.  
Questions that we discuss in this dissertation are: 
1. Should we treat populations as a group of single cells 
or as an interconnected social system? 
The populations are a higher layer of the systems hierarchy 
than single cells and therefore, according to the general systems 
theory, possess the features directly derived from the lower layer 
of single cells. But can we derive all the features of the cell 
populations from a sum of single cells features? The holistic 
philosophy is based on the assumption that the higher hierarchical 
system possesses the properties that derive from the lower layers 
but can’t be directly represented as a sum of them. Our hypothesis 
is that the population dynamically behaves differently from the 
single cells in response to same stimuli and produced a 
coordinated response, which is an emergent property of the 
population. This behavior has evolutionary importance at the 
populational level because provides more robust responses. 
2. How do different cell types respond differently to the 
same signal? 
All cell types share the same genetic background but possess 
different phenotypic feature and are responsible for different 
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functions within the body. There are various mechanisms to 
achieve this variety, including epigenetics and posttranslational 
modifications among others. At the end, the cells obtain different 
transcriptional profile according to their functions. I propose that it 
is mainly through the connections in their molecular networks, 
which make the difference. The signal transduction networks 
operate differently because they are constructed with the same 
nodes but different dynamic parameters (e.g. epigenetic regulation 
of specific kinases). In other words, the signal from certain external 
signals passes through the same molecules but by different 
signaling pathway routes or with different kinetic properties.  
3.  Why does negative feedback loop is such a common 
motif in cytokine signaling and how the oscillatory dynamics is 
regulated? 
Frequently the kinetics of the pathway is dependent on the 
positive and negative feedbacks, which orchestrate oscillatory 
dynamics of the cascade that regulates the translocation of TF and 
modulate gene expression. Oscillatory behavior has evolutionary 
advantages in the noisy environment the cells have to analyze the 
signal. I propose that the kinetic oscillations are the mainstream 
behavior of cytokine signaling in mammals and are insensitive to 
the ODE model parameter variations. 
4.  How do nuclear translocation parameters may 
influence the kinetic behavior of a signaling pathway? 
The nucleus of eukaryotes is separated from the cytoplasm 
by the nuclear membrane. The membrane regulates the import and 
exports to and from the nucleus by creating the gradient and act as 
a mechanical barrier. As part of the iterative cycle of systems 
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biology research (from theory to experiments and back), I realized 
that dynamical features of the nuclear transport of TFs are 
important variables in the signal transduction kinetics.  The 
nuclear transport may be a kinetic buffer for the signal 
transduction events. I hypothesize that these parameters of the 
nuclear transport may determine the dynamics of the systems, 
including oscillatory/damned oscillatory regimes. The dynamic 
analysis of TF translocation is a readout of the activation of the 
pathway and can be used as a biomarker of the activation of the 
pathway and the effects of therapies targeting this pathway. 
 
In this work we examine these hypotheses and provide proof 
of concept studies to validate them. 
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Objectives 
Information transmission through signaling pathways is a 
dynamic process in which signals of activation are transmitted 
through phosphorylation reactions. The general goal of the thesis 
is understand how the information is transmitted through 
prototypic signaling pathways which are relevant for the 
pathogenesis and therapy of MS, namely the IL-6, IFNbeta and 
PI3K (Sgk-Akt-Foxo3a) pathways, with different layers of system 
complexity. A second goal is to make use of these pathway models 
for translational research, in order to understand how drugs target 
these pathways and for identifying biomarkers of the response to 
therapy of MS.  
The specific objectives are: 
1. To model the dynamical features of IL-6 pathway at 
population and single cells level in order to assess the 
emerging properties of cell population signaling. 
2. To assess the differences of cytokine signaling pathway in 
the two main immune cell subtypes T cells and 
macrophages, by building and validating a Boolean 
network of IFNbeta signaling; 
3. To analyze the oscillatory dynamics of IFNbeta signaling by 
developing a kinetic model of Type I IFN signaling which 
can explain the observed dynamics from our experiments 
and determine the properties that are crucial for the 
oscillatory dynamic 
4. To evaluate the role of nuclear translocation of TF (Stat1 for 
IFNbeta pathway and Foxo3a for PI3K pathway) as 
modulators of the pathway kinetics and the possibility to 
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use it as a potential drug target or dynamical biomarker of 
response to therapy. 
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Materials and methods 
Materials and reagents 
Cells were obtained from ATCC library, mouse recombinant 
IFN-beta was purchased from Cell sciences, lipopolysaccharide 
from Escherichia coli and poly(I:C) salt was purchased from Sigma-
Albrich, lipofectamine 2000, Hiperfect transfection agent were 
purchased from QIAGEN, Taqman PCR master mix, VIC-dye 
GAPDH endogenous control, IRF1, Socs1, Stat1, Stat2, MX1, 
OAS1a pre-designed FAM-dye assays were purchased from 
Applied Biosystems, total Stat1 and Stat1(pTyr701) antibodies and 
beads, cell detection kit for xMAp assays were purchased from 
Merck Millipore (Billerica). Alexa Flour 647 Stat1 (pTyr701) and PE 
Stat1 N-terminal anti-Mouse antibodies and all buffers for 
cytometry were purchased from BD biosciences. APC-labeled 
IFNAR1 antibody was purchased from Biolegend.  
Human samples 
The blood samples were obtained from MS patients and 
healthy controls according to the informed consent. These studies 
were performed under the frame of CombiMS project and 
approved by Ethic committee of the Hospital clinic of Barcelona . 
The blood was used to extract PBMCs using standard Ficoll 
gradient protocol. PBMCs were maintained in full medium 
(RPMI+5%SBF+penicillin/streptomycin) for 6-24 hours and 
stimulated with appropriate stimulator for indicated times (see 
results).  
Cell culture and stimulation 
Mouse leukemic monocyte macrophage cell line RAW 264.7 
and mouse fibroblasts 3T3 cell lines were purchased from ATCC 
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and maintained in DMEM medium complemented with 10% fetal 
bovine serum and 1% antibiotics at 37ºC and 5% CO2.  The cells 
were passed every 2-3 days and maintained in 20-80% surface 
coverage. One day before the stimulation the cells were seeded in 
12 well plates in concentration 1 x 106 cells/well. The cells were 
stimulated with 1000 units of recombinant mouse IFN-beta, 15 μg 
of LPS for different times or 15 μg of poly (I:C) solution. At the end 
of stimulation supernatants or cells were collected for further 
analysis. The same amount of PBS was added at the corresponding 
time-points to the control samples.  For the Boolean model we 
used Jurkat and THP-1 human cell lines obtained from ATCC cell 
bank. PBMCs from healthy controls and patients with MS were 
obtained and processed according to standard protocol.  3T3 
fibroblasts were cultured in 24-well tissue culture plates in DMEM 
containing 10% fetal bovine serum (FBS). Prior to stimulation, the 
cells were serum-starved for two hours by replacement of media 
with DMEM alone. At t=0, IL-6 (BD Biosciences) was added to 
wells at 100 ng/ml, 10 ng/ml and 1 ng/ml. To separate 3T3 
cultures, IFN-γ (BD Biosciences) was added at 100 ng/ml and 1 
ng/ml. Control 3T3 fibroblasts were cultured without IL6 or IFNγ. 
To assess intracellular signaling pathways, cells were removed at 
regular intervals during the course of eight hours from the wells 
by the addition of cold 0.25% trypsin (Invitrogen) and fixed at 
room temperature for 10 minutes with a PBS solution containing 
1.6% paraformaldehyde (Electron Microscopy Sciences). Following 
fixation, cell suspensions were washed with PBS and ice-cold 
methanol was directly added to a final concentration of 90% 
methanol.  
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  RT-PCR 
Cell lysates were prepared with QiaShredder columns and 
total RNA was isolated using standard Qiagen Rnaesy Mini kit 
protocol. Equal amount of total RNA was added to each reverse 
transcription reaction tube (High-Capacity cDNA Reverse 
Transcription Kit from Applied Biosystems and cDNA was used 
for a second step of RT-PCR. Results were analyzed using relative 
2CTT method normalized to a GAPDH endogenous control (VIC-
dye primer-limited control from Applied Biosystems) as described 
before [74]. All the qRT-PCR experiments were performed in 
triplicates and repeated three times independently. For 3T3 cell 
line, frozen cells were thawed, disrupted and homogenized using 
QIAshredder spin column and RNA were extracted using 
standard manufacturer spin protocol for animal cells with DNAse 
digestion using RNeasy mini kit (QIAGEN). The amont of total 
extracted RNA was measured by nanodrop and used for reverse 
transcription (High Capacity cDNA Archive kit from Applied 
biosystems 4322171) in concentration 100 ng/mcl. The second step 
of real-time PCR was performed using designed primers and 
probes for Socs1 and Socs3 were ordered from SIGMA. 
Predeveloped VIC-dye TaqMan Endogenous control for mouse 
GAPGH (Applied Biosystems) was used to normalize the 
expression of Socs genes. 50 ng/mcl of cDNA obtained from 
reverse transcription was used for each real-time PCR reaction. 
The standard 2−∆∆Ct method [75] was used to calculate the 
results.  
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Western blot and quantification 
Western blot (WB) was performed using polyclonal rabbit 
anti-mouse pStat1 and Stat1 N-terminal antibodies (Abcam) using 
standard WB protocol. Western blot results were quantified using 
ImageJ software (http://rsb.info.nih.gov/ij/index.html) using the 
method of Luke Miller 
(http://www.lukemiller.org/journal/2007/08/quantifying-
western-blots-without.html) 
 
ELISA and xMAP multiplexing assays 
IFN-beta in culture supernatants and Socs1 protein 
concentration in cell lysates were measured by standard sandwich 
ELISA with anti-mouse Socs1 antibodies  (Abcam). IRF1 protein 
concentration in cell lysates was measured by in-cell ELISA using 
the kit (Thermo Scientific) Stat1 total protein and phosphorylated 
state (Tyr701) concentrations (nuclear and cytoplasmic together) 
were measured using xMAP assays and read in Luminex 201 
platform using standard vacuum separation protocol (Millipore). 
xMAP experiments were repeated twice.  
 
Flow cytometry and ImageStreamX imaging system 
Cells for flow cytometry were stimulated with 1,000 
Units/ml of IFN-beta as stated before and fixed immediately after 
stimulation. IFNAR1 receptor on the surface of the RAW 264.7 
cells was marked using APC-labeled anti-IFNAR antibody. The 
mean fluorescent intensity was calculated using FlowJo software. 
For Stat1 staining cells were fixed immediately after stimulation in 
order to preserve phosphorylation and then permeabilized using 
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Perm III buffer (BD biosciences). Samples were stained 
simultaneously with anti-Stat1 (pTyr701) and anti-Stat1 total (N-
terminus) antibodies. The mean fluorescent intensity, the percent 
of staining-positive cells, the medians and the standard deviation 
were calculated using FlowJo software and the raw single-cell data 
were extracted to plot the histograms and further analysis.  To 
determine the quantity of pStat1 shuttling to the nucleus after 
IFNbeta injection in patients in MS we used ImageStreamX 
imaging system that allows visualizing the co-localization of two 
different molecules using flourchrome-conjugated antibodies (fig. 
17). The nucleus was labeled with DAPI and pStat1 with mouse 
anti-human Alexa Flour 488 pStat1 (Y701) antibody.  
 
Figure 17 ImageStreamX technology. The method allows to quantify the 
nuclear translocation in single cells. 
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Mathematical modeling  
Boolean model  
To build the Boolean network of antiviral and antibacterial 
immune response we used the workflow developed by Dr Saez-
Rodriquez and described in [76]. In brief, we developed a 
Preliminary Knowledge Network (PKN) based on text-mining, 
databases and previous studies. This PKN was represented as a 
topology is Cytoscape using “sif” file (tab-separated file with 1 and 
-1 assigned to each link between connected molecules). The 
experimental results were transformed in the MIDAS files and 
used to refine and fit the PKN using the CellNoptR software. The 
workflow is present on the fig. 18.  
 
Figure 18 The simplified workflow to obtain the specific logic model 
based on the experimental data. See details in the text. 
 
The experiments were designed to fit the requirements of the 
CellNoptR software. The stimuli, inhibited and measured 
  47 
molecules are labeled on fig. 19. The PKN was evenly covered by 
inhibitor perturbations and available for measurements 
phosphoproteins. The experiments were performed for 2 
timepoints (15 and 60 min) and analyzed using two-timepoint 
algotirhm. The experimental data were normalized to endogenous 
control (GAPDH) and to the time 0 measurements according to the 
package manual.  
 
 
Figure 19 The PKN used for the Boolean modeling of immune response 
network in THP1 and Jurkat cell lines. Stimulus marked in green, measured 
phosphoproteins – in purple, inhibited proteins in red rounds, transcription 
factors in yellow, measured total proteins - in light blue. The analytes are 
labeled as following Green – stimulus: IFNbeta, IFNgamma, LPS, polyC, Blue 
– phosphoproteins: p38, Mekk, Stat1, Stat2, mTor, AKT, Jak1, Yellow – 
Lueferase reporter assay targets: GAS, ISRE, IRF-E, Red circles – the proteins 
to inhibitor: Stat1, p38, PKCa, AKT, Jak1, TYK1 
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Figure 20 The example of the experimental data visual representation by 
DataRail. Rows - measured phosphoproteins. Columns: up - stimulus, down - 
inhibitors used during the experiment. The graph inside represents the 
change in the signal over time (from 0 to 15 minutes)  
The following workflow was proposed to fit the models to 
the data (adopted from [77] with modifications):  
1. Build the PKN 
2. Map available stimulus/inhibitors and targets  
3. Design the experiments  
4. Perform first set of trial experiments 
5. Represent the data in MIDAS format 
6. Normalize data to use in Boolean logic models 
7. Perform simulations predesigned PKN against 
experimental data with CNO 
8. Use preliminary data to add new links and refine the 
network 
9. Repeat stage 7 with refined network 
10. Refine the experimental design according to the 
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preliminary results 
11. Perform the all the experiments  
12. Repeat stages 5-9 with each dataset 
We converted our data to MIDAS file format accepted by 
DataRail (fig. 20) and described out PKN in a sif file that can be 
visualized using Cytoscape. We use DataRail software 
(http://code.google.com/p/sbpipeline/) to preprocess the data 
and CNOptR software to fit the model to experimental data. All 
the scripts and functions were written in R. The CellNoptR and 
other packages were downloaded from Bioconductor. Graphviz 
and Cytoscape were used for visualization of the models. The best 
fit was compared manually to each other to determine the 
differences between cell subtypes.  
ODE model 
The ODE model of IFNbeta and IL6 pathways and 
simulations were run in MATLAB using the ODE15s solver 
(Matlab codes are provided in the supplementary data). The 
stability analysis of the dynamical system was performed with 
custom-made Matlab codes.  
To establish the ordinary differential equations (ODE) model, 
which explains the behavior of the model, we need to minimize 
the number of parameters. We used Matlab scripts for model 
stimulation.  
 We used different methods to obtain the parameters for the 
model. Some of the parameters were estimated using experimental 
data from previous knowledge (table 2) [48] while others were 
fitted manually according to the experimental results from RAW 
264.7 cell line.  
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Parameter Value Reference 
bdeph 15 min half-life [78] [79] 
n 3 [80] 
u 1 [81] 
λr 2.82 hour half-life This work 
λf 1.23 hour half-life [82] 
A initial 105 molecules/cell [83] 
S initial 700-900 
receptors/cell 
[84] 
λStat protein 24 hour half-life [85] 
λF 30 min half-life [86] 
f initial 1 molecule/cell [87] 
Table 2 Parameter values obtained from the literature 
 
For IL6 model we used stochastic simulations by Gillespie’s 
algorithm to simulate  heterogeneity in cells by varying randomly 
initial conditions for STAT3 molecules and the number of active 
receptors available/ or stimulated by cytokine. 
Parameter space exploration for Foxo-Akt model 
The model of Sgk/Akt-Foxo3a was simulated in Matlab. 
Additionally we used the workflow explained in the paper by 
Gomez-Cabrero et al. to explore the whole parameter space of the 
system [32]. The workflow was implemented in MATLAB. The 
certain parameters were fixed according to the previous 
knowledge (see sup. table 6), and the others were explored in the 
all positive parameter space. The initial conditions were fixed 
according to sup. table 5. 
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Results 
Chapter 1. Theoretical considerations on pathway dynamics 
in individual cells and cell populations 
The models designed in the other chapters of this thesis are 
examining the behavior of the system in the presence of certain 
stimuli without taking into account the variations of the response 
of single cells. The other side of the coin is the population behavior 
that we actually see in most of the experiments.  
There are three aspects affecting the population behavior as a 
whole: 
1. The kinetics of the behavior of each member of the 
population (each cell) (fig. 21). The cells may be synchronized in 
time or have desynchronized oscillations, which won’t be seen on 
the populational level; 
2. The effects of the members of the population (cells) 
on each other; 
3. The environmental noise affecting the population 
(stochastic inputs). 
 
Figure 21 Population versus single cells oscillations. The second peak may be 
present in single cells, but missing in populational level due to 
desynchronization. 
  52 
Using the dataset from Prof Garcia-Ojalvo group from UPF 
we performed a case study of the dynamics of the population 
versus single cells in IL6 signaling pathway (manuscript in 
preparation). We explored a dynamic feature of the Stat/Socs 
system that has been reported as ultradian oscillations by Yoshiura 
et al [88]. Yoshiura et al. showed that serum stimulation triggers 
oscillations due to the interplay between active Stats and Socs 
alone. That is, oscillations in Socs3 levels required cyclic 
phosphorylation of Stat3 and vice versa, periodic activation of 
Stat3 depended on Socs3 oscillations. 
The dataset we used consists of time-resolved measurements 
of Socs3 RNA by RT-PCR and Tyr-phosphorylated Stat3 (Stat3-P) 
by Flow Cytometry in serum-stimulated fibroblasts for extended 
time intervals (fig. 22). Oscillations showed a period of 
approximately two hours. Oscillations of the repressor, Socs3, 
affected both its mRNA and protein concentrations. In particular, 
approximately in-phase oscillations of Stat3-P and Socs3 mRNA 
were followed by one hour-delayed oscillations in the levels of 
Socs3 protein..  
The fact that oscillations exist at the population level 
indicates that cells acted in a synchronized fashion after serum 
treatment (otherwise, averaging would have rendered oscillations 
unobservable).  
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Figure 22 Median levels of phosphorylated Stat3 (A) in mouse 3T3 
fibroblasts measured by flow cytometry in the absence of stimulation (grey), 
stimulated with IL-6 (1 ng/ml: blue, 10 ng/ml: green, 100 ng/ml: red). Standard 
errors (SE) are smaller than 0.02 in all cases, therefore error bars have been 
omitted. Mean fold change in the expression of Socs3 (B) in response to IL-6 
is also shown, as measured by RT-PCR, with error bars corresponding to the 
SE of two experimental replicates. 
The experiments show that the oscillation period is 
insensitive to cytokine levels (fig.22). The experimentally observed 
oscillations, however, were reported only at the cell population 
level and were not self-sustained: a few hours after stimulation the 
oscillations in the population were seen to disappear.  In order to 
verify that this behavior is consistent with our model, we now 
consider a population of independent cells reacting to identical 
environmental conditions.  
From experimental results of pStat3 after IL6 stimulation, we 
derived a histogram of single cells distribution (fig. 23), which 
shows that not only the mean (black dots over the green plots), but 
also the distribution differs in different timepoints. To better 
understand the nature of the distribution we calculated the 
coefficient of variation (CV) from the single cell flow cytometry 
data (fig. 25). 
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Figure 23 The single-cell distribution histogram for pStat3 after IL6 
stimulation of 3T3 fibroblasts. Based on single-cell flow cytometry results  
We developed an ODE model of the IL6 pathway graphically 
represented on the fig. 24. Our ODE model consists of key 
signaling processes:  
• the activation of IL6 receptors by cytokine 
• the subsequent phosphorylation of Stat3 and its translocation 
to the nucleus 
• the dephosphorylation inside the nucleus and the export to the 
cytosol in the dephosphorylated state, closing the loop for Stat3 
in cytosol.  
• At same time, we have considered the repressor module from 
SOCS3 gene expression as a negative feedback loop, which 
inhibits the phospho cascade from the active receptor. 
• All species of subject of degradation 
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Figure 24 Graphical reppresentation of IL6 signaling pathway model 
Our model displays the following features: i) the model leads 
naturally to a stable limit cycle with period and phase profiles that 
match the values experimentally observed, (ii) the limit cycle exists 
with a markedly robust period for a large range of parameter 
values, such as the amount of cytokine and of total Stat proteins, 
and (iii) stimulation of the pathway by the sudden addition of 
inducer leads to the synchronization of a population of already-
oscillating cells, in a dose-dependent manner. 
The model from fig. 24 can be represented by a system of 
differential equations (ODEs): 
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dAc
dt
= bexp * An + bdeph * Apc − bph * S * (Ac /kA ) /(1+ (Ac /kA ) + power(R /kI ,q)) − λSTAT 3 * Ac
dApc
dt
= bph * S * (Ac /kA ) /(1+ (Ac /kA ) + power(R /kI ,q)) − bimp * Apc − bdeph * Apc − λSTAT 3 * Apc
dApn
dt
= bimp * Apc − bdeph _ nucleus * Apn − λSTAT 3 * Apn
dAn
dt
= bdeph _ nucleus * Apn − bexp * An − λSTAT 3 * An
dr
dt
= br * power(Apn /kr,n) /(1+ power(Apn /kr,n) − λr * r
dR
dt
= bR * r − λR * R  
We simulated the model dynamics on a populational levels 
(fig. 25 in black).  
CV is calculated as standard deviation divided by the mean 
for each measured timepoint (fig. 25 on the right) CV is a measure 
of the difference in the response of the cells to stimuli at the same 
timepoint. It shows that the desynchronization of the cells occur in 
15 minutes after stimulation. So all cells get activated at the same 
time, but at the different level (amplitude of response).  Then CV 
drops down and goes up again. The second minimum of the CV at 
200 min corresponds to the second peak of the median response. It 
means that the cells get more synchronized at the second peak 
then at the first one. After the second peak the cell desynchronize 
again and get to a steady state of desynchronization. This kinetic 
profile remains the same with different concentrations of IL6. 
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Figure 25 Model simulations versus experimental data for pStat3. Fold 
change of phosphorylation levels (on the left) and coeffecient of variation 
(right). Green lines correspond to experimental data and black – to the 
simulation of the model. 
This observation proofs that all the cell are strongly activated 
shortly after the stimulation (at 15 min), but the amplitude of the 
activation vary a lot from cell to cell (high CV on fig. 25 right). On 
the second peak the response is lower (lower peak at 200 min on 
fig. 25 left), but the CV is also reaches local mínimum (200 min on 
fig. 25 right). The model could reproduce this variability changes 
(fig 25 in black).  
Biologically speaking, the second round of cells activation 
corresponds greatly to the cell synchronization and the population 
acts as an entire system rather than a collection of differently 
responding cells. It may be important for the correct immune 
response.  
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Chapter 2. Differential role of IFNbeta signaling in T cells 
and macrophages modeled with Boolean networks 
Boolean modeling of IFN pathways in Jurkat and THP1 cell lines 
IFNbeta signaling pathway interacts with many antiviral and 
antibacterial response pathways, becoming a part of a bigger 
molecular network. To answer the question on how this network is 
organized in different immune cell subtypes we used the 
workflow developed by Prof Saez-Rodriquez (see introduction and 
methods sections). We developed a simplified topology of the 
interactions between IFNbeta, IFBgamma, TLR3 and TLR4 
pathways based on previous studies and data-mining. This 
topology is called the Preliminary Knowledge Network (PKN) (see 
methods and fig. 19). In this PKN we labeled the stimuli, the 
intermediates and the genes as well as feedback loops and 
crosstalk between different pathways in the network. The aim of 
Boolean modeling approach is to predict the interactions between 
the molecules in the network in the concrete conditions or cell 
types. In short, our objective was to build cell-specific networks of 
type 1 IFNs and inflammation signaling pathways in T cells and 
macrophages. We used the T cells (Jurkat) and macrophage-like 
(THP1) cell lines to obtain the experimental data. The cells were 
challenged with the combinations of different stimuli and 
inhibitors and different phosphoproteins, which were measured 
by XMAP bead assays under these conditions (labeled in fig. 19). 
See methods sections and [89, 90] for more details. 
The data obtained from the cell lines and the goodness of 
fitness of the model is shown in the figures 26 and 27.  
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Figure 26 Experimental results and model fit for Jurkat cell line. Fit of 
model predictions (dashed blue lines) to data. The color of cells represents the 
quality of fit (green - perfect fit, red - the model couldn't explain the data). 
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Figure 27 Experimental results and model fit for THP1 cell line. Fit of 
model predictions (dashed blue lines) to data. The color of cells represents the 
quality of fit (green - perfect fit, red - the model couldn't explain the data). 
After applying the CellNoptR algorithm (see methods) to the 
PKN and experimental data for two different cell lines, we 
obtained the logic models and topologies for each cell line (fig. 28 
and 29). 
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Figure 28 Logic model fitting the data from Jurkat cell line. Confirmed 
links are in green and blue.  
 
Figure 29 Logic model fitting the data from THP1 cell line. Confirmed 
links are in green and blue.  
 
The models can be represented as scaffolds (fig. 30) that 
allow assessing the differences in the signaling between Jurkat and 
THP1 cell lines.  
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Figure 30 Scaffolds obtained from logic models for Jurkat cell line (up) 
and THP1 cell line (down) 
 
As many of the main signaling channels are the same (it can 
be expected due to the close relationship between all immune cell 
subtypes), there are clear differences between the two scaffolds. 
For THP1 the connection IFNbeta-Jak1-Stat2 is direct. In Jurkat cell 
line the Jak1 is not directly triggering Stat2 activation. The 
activation in this case is due to other intermediates. In THP1 we 
see the activation CREB by IFNbeta, while in Jurkat we could not 
detect this effect. IKK is directly activating NFkB in Jurkat cells, 
but not in THP1 cells. There are other differences in signaling 
which may explain some of the difference in the response of 
immune cell subtypes in vivo (see discussion).  
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The pipeline to apply Boolean modeling to the clinical data 
The approach was applied to the stimulated human PBMCs 
from healthy individuals to validate the clinical application of 
logic modeling.  
The difference in type I IFN signaling pathway between 
immune cell subtypes may be crucial for the IFNbeta treatment cell 
response. For this reason we developed a method to apply the 
same approach for clinical data from individual patients. The 
challenge of the clinical data is the diversity between individuals 
in the cohort that produce noisy data.  
For this reason we proposed the following algorithm for the 
analysis of 2 groups of individual clinical readouts of homogenous 
data. We applied the CellNoptR package to the simulated 
experimental results from [91] mimicking patients’ dataset. The 
PKN and the simulated datasets were used to optimize the method 
of averaging and comparing resulting network topologies.  
The method was based on averaging bitstrings 
corresponding to each model generated from each dataset.  The 
bitstring is a vector consisted of 0 and 1 values corresponding to 
not-confirmed and confirmed by the experimental data links 
between different species. After CellNoptR simulation a bitstring 
was assigned to each toy set corresponding to an “individual”. 
The average model bitstring for each cohort was calculated 
using the following formula: 
 
<n>= 1/SUM(MSEi)*SUM(1/MSEi*bsi)  
 
where <n> is the resulting average bitstring vector, N – 
number of models in the dataset, MSE – mean squared error of the 
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best model based on the i-dataset, bs – the best model bitstring for 
the i-dataset. The resulting normalized average bitstring <n> was 
used to build the graphical representations of the models. The 
difference was calculated using the following formula: 
<dif> = abs (<n1>-<n2>) 
where <n1> and <n2> are the bitstrings for average group 
models calculated previously and the <dif> is the resulting 
bitstring, graphically represented on fig. 31 with numbers on the 
edges meaning the “strength” of the differences 
  
Figure 31. Differences between two average networks of simulated 
patients cohorts 
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The graph representing the differences between two dataset 
groups (20 datasets each) is shown on fig. 31. I found that the main 
difference were the links between TNFa and p38 and map3k and 
p38 (solid lines with the weight of 95 on fig. 31).  
The developed approach can be used on the data from a big 
cohort of patients when it’s necessary to see differences in the logic 
model between two groups. We are applying this method to the 
data from over 250 human samples with different MS subtypes to 
recognize the differences in molecular signal transduction and 
propose possible combinational therapies (CombiMS FP7 project 
http://combims.eu). 
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Chapter 3. Kinetic model of the IFN-beta signaling pathway 
in macrophages 
One of the main interests in MS pathway studies is IFNbeta 
pathway due to wide usage of IFNbeta as a first choice drug for 
MS. The response to IFNbeta by MS patients is very limited and 
biomarkers and combinations are necessary to increase 
effectiveness of the treatment.  For improving understanding on 
the IFNbeta pathway we developed a dynamic ODE model, which 
is focused on the implication of different parameters in the 
pathway dynamics.  
In order to identify the critical elements of the signaling 
pathway that are responsible for the transient oscillatory behavior 
observed in our experiments in macrophages upon IFN-beta 
stimulation, we built an ODE model based in biological 
knowledge and experimental data. To minimize its complexity, we 
pursued the minimal system explaining the experimental 
observations, instead of a full descriptive system [92]. The model 
was not used to reproduce sustained endogenous IFN activation 
after viral infection, although it could be applied to that scenario. 
We developed the model of IFN-beta signaling pathway using a 
systems biology approach and finding the key pathway 
bottlenecks, which could be proposed as possible IFN-beta 
treatment response markers [48]. 
In order to analyze the effects of microbial infection in the 
type I IFN pathway, we stimulated the murine macrophage-like 
cell line RAW 264.7 with the lipopolysaccharide (LPS) endotoxin, 
and measured the release of IFN-beta at different time points by 
ELISA. We observed (fig. 32A, blue line) that IFN-beta release 
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increases shortly after LPS stimulation, fluctuating around a 
markedly non-zero level, which is sustained for long times. The 
initial increase in the release of IFN-beta is accompanied by a 
significant increase in the levels of phosphorylated Stat1 (fig. 32B). 
We also simulated the effects of viral infections in the endogenous 
IFN production, stimulating RAW cells with poly (I:C). We 
observed that poly (I:C) induced also an increase in the levels of 
IFN-beta in RAW 264.7 cells, although to a lower level than LPS 
(fig. 32A, red line).  
 Figure 32 IFN-beta induction after microbial or viral trigger in macrophage 
cell line. IFN-beta levels in Raw cell culture supernatants after stimulation 
with LPS (15 μg/ml) (blue) or Poly (I:C) (25μg/ml) (red) versus non-stimulated 
control (black line) in the first 6 h and in some later times from 12 h (A); B) 
Western-blot showing phosphorylated and total Stat1 levels after LPS 
stimulation (15 μg/ml) of Raw cell line analyzed by Western-blot and 
  69 
quantified by densitometry. All experiments were performed in triplicates 
and repeated at least two times independently. 
 
We built a dynamic model of the IFN-beta signaling pathway 
using experimental data of protein and mRNA concentration 
measurements in vitro and previous biological knowledge. The 
model is based on ordinary differential equations (ODE) and 
predicts the behavior of the IFN-beta signaling pathway during 
time. The simple model included the main and most important 
parts of the pathway, such as Stat1 phosphorylation, Socs1 
inhibition of Stat1 phosphorylation and others.  The model was 
focused on the self-regulatory events in the pathway. We verified 
the model with the experiments with macrophage-like murine 
RAW cell line. 
 
Figure 33 Mathematical model of type I IFN signaling pathway. 
Graphical representation of the mathematical model of type I IFN signaling 
pathway. 
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The ordinary differentiation equations for the model showed 
on fig. 33 are: 
 
 
 
We performed time series analysis of the phosphorylation of 
Stat1 and levels of total Stat1 and Socs1 by Luminex assays and 
Elisa (fig. 35) and levels of Stat1, IRF1 and Socs1 mRNA after IFN-
beta stimulation by RT-PCR (fig. 34). We observed that 
phosphorylated Stat1 levels increased rapidly after IFN-beta 
induction (fig. 35A). The increase was significant as soon as 2 min 
after stimulation and reached a maximum at 10–15 min after 
stimulation, followed by a decrease that correlates with a 
substantial increase in the concentration of the SOCS1 protein (fig. 
dS=dt ¼ bs−λsS
dA=dt ¼ b expApn þ bdephApc
þ bAa− bphSA=kA1þ A=kA þ R=kIð Þq −λSTATA
dApc=dt ¼ bphSA=kA1þ A=kA þ R=kIð Þq −bimpApc  bdephApc
−λSTATApc
dApn=dt ¼ bimpApc−b expApn−λSTATApn
dr=dt ¼ br
Apn=kr
 n
1þ Apn=kr
 n −λrr
dR=dt ¼ bRr−λRR
df =dt ¼ bf
Apn=kf
 m
1þ Apn=kf
 m −λf f
dF=dt ¼ bF f −λFF
da=dt ¼ ba F=kFð Þ
u
1þ F=kFð Þu −λaaþ BSTAT
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35C). A second, smaller peak was visible at around 180 min, 
followed by a subsequent decrease back to the baseline level after 
around 360 min. The quick decrease of phosphorylated Stat1 levels 
is in agreement with previous studies pointing to the activation of 
the negative feedback loop mediated by SOCS1 protein, which 
suppresses the phosphorylation of Jak1 and TYK2 proteins and 
prevents the formation of Stat-dimers [93]. The total level of Stat1 
protein, on the other hand, is maintained practically constant until 
around 200 min after stimulation, after which it starts to increase 
slowly until the end of the experiments (fig. 35B). Stat1 mRNA 
levels grew quickly and continuously, starting sharply at around 
75 min and leveling off after 200 min (fig. 34A). This increase in the 
mRNA level of Stat1, as soon as 1 hour after the induction of 
response by IFN-beta, agrees with the influence of the positive 
feedback loop IRF1 – Stat1 [94] and confirms the importance of this 
circuit for the pathway dynamics. 
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Figure 34 Gene expression levels of Stat1, IRF1 and Socs1 after IFN-beta 
stimulation and the corresponding simulations from the ODE model. A-C) 
Stat1, IRF1 and Socs1 RNA concentration in cell lysates were measured by 
RT-PCR in the Raw cells stimulated with IFN-beta (1000 units/ml); A) Stat1 
RNA levels in the Raw cells stimulated with IFN-beta; B) IRF1 RNA levels in 
the Raw cells stimulated with IFN-beta; C) Socs1 RNA levels in the Raw cells 
stimulated with IFN-beta. We plot here one out of three independent 
experiments, which were performed in duplicates. D-F) Model simulation 
and sensitivity analysis with ± 20% change for all parameters (shaded areas) 
for Stat1 (D), IRF1 (E), and Socs1 (F) RNA levels. 
To analyze the expression of regulatory genes of the type I 
IFN pathway, we measured the levels of two downstream Stat1 
genes, SOCS1 (responsible of the negative feedback) and IRF1 
(mediator of the positive feedback). We observed an oscillatory 
behavior of SOCS1 mRNA during the first 360 minutes after 
stimulation, with clear peaks at around 90 min and 250 min, before 
returning to baseline levels (fig. 34C). On the other hand, IRF1 
shows different dynamics, with its concentration raising quickly 
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between 30 and 120 min, then reaching a plateau and decreasing 
more slowly after 250 min (fig. 34B). We also quantified the 
expression levels of other downstream effector IFN-induced genes, 
such as MX1 and OAS1b, but did not identify any activation of 
their transcription in the RAW 264.7 cell line after IFN-beta 
stimulation. Our observations show that in the RAW 264.7 cell line 
the main activated genes were the ones controlled by the Stat1-
Stat1 homodimer (IRF1 and SOCS1) and containing GAS elements 
in their promoter region. These genes are mainly responsible for 
the antimicrobial activity of the cells [95].  
Then, we compared experimental results with mathematical 
model simulations in order to assess the agreement of the 
dynamics at the qualitative level. Experiments uncovered several 
important features of Jak/Stat signaling dynamics during the first 
eight hours after treatment with IFN-beta. For example, our results 
showed the transient oscillatory nature of Stat1 activation (pStat1), 
with a fast increase in cytosol concentration early after stimulation 
(within the first hour), followed by a secondary concentration peak 
at around 200 min. A key Stat1 transcription target such as Socs1 
also showed two peaks of expression (correlated in time to the 
pStat peaks) at around 90 min and 250 min after stimulation, 
whereas another important target, namely IRF1, exhibited a more 
bell-shaped plateau signal. 
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Figure 35 Activation of type I IFN pathway by IFN-beta in Raw cell line 
and the corresponding simulations from the ODE model. A-C) pStat1, Stat1 
and Socs1 protein concentration in cell lysates were measured by Luminex, 
Flow cytometry or ELISA after stimulation with IFN-beta (1000 units/ml). The 
data was normalized to the maximum level. A) pStat1 protein concentration in 
the Raw cells stimulated with IFN-beta; (B) Total Stat1 protein concentration 
in the Raw cells stimulated with IFN-beta; C) Socs1 protein concentration in 
the Raw cells stimulated with IFN-beta. We plot here one out of three 
independent experiments, which were performed in duplicates.  D-F) Model 
simulation and sensitivity analysis with ± 20% change for all parameters 
(shaded areas) (D: pStat1; E: Stat1; F: Socs1).  
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Chapter 4. IFNbeta model analysis and nuclear translocation 
as a modulator of the IFNbeta pathway kinetics 
 
We performed computer simulations using different 
conditions and parameters as well as sensitivity and bifurcation 
analysis of the developed IFNbeta ODE model. The bifurcation 
analysis indicated the possible implication of nuclear translocation 
of pStat1 for the correct oscillatory activity of the cells upon the 
IFNbeta stimulation in vitro. This finding led us to the hypothesis 
of alteration of the nuclear translocation process in the response to 
IFNbeta therapy.  
The model allows us to interpret the second peak observed 
experimentally in pStat1 and SOCS1-mRNA levels in terms of an 
underlying damped oscillatory dynamics. We now ask which are 
the mechanisms that lead to oscillations, on the one hand, and to 
damping, on the other hand. A well-known gene circuit 
architecture that leads to oscillatory behavior is a combination of 
positive and negative feedback loops. As mentioned above, our 
model contains a negative feedback loop mediated by SOCS1. We 
can examine in the model the effect of not having this feedback by 
eliminating SOCS1 signaling from the model. The results show 
that this negative feedback is required for the oscillatory behavior 
to arise: its absence leads to a transient plateau of high pStat1 
levels during the first 4–5 h of IFN treatment (fig. 36B), which 
contrasts with the relaxation oscillator behavior obtained for our 
basal parameter values (fig. 36A), which is a closer match to the 
experimental observations (fig.  35-35). The model also contains a 
positive feedback loop mediated by IRF1. This loop, however, does 
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not appear to be crucial for the oscillatory behavior of pStat1 (fig. 
36C), and is only necessary to reproduce the experimentally 
observed increase of Stat1 expression (fig. 34). 
 
Figure 36 Type I IFN pathway model simulations during the first 8 hours after 
IFN-beta stimulation. (A) Model simulations showing oscillations of total 
(nuclear plus cytoplasmic) pStat1 protein, Socs1 mRNA expression (dashed 
line) and Stat1 mRNA expression (dotted line). (B) Corresponding 
simulations where the Socs1-mediated negative feedback is disrupted by 
assuming an infinite value of the repression threshold kI. (C) Corresponding 
simulations not including the IRF1-mediated positive feedback, by assuming 
a zero value of the Stat1 activation threshold kF (which leads to saturation of 
the corresponding Hill function, so that the dependence of an expression on F 
is removed). 
The temporal evolution of the phosphorylation of Stat1 can 
be crucial for understanding the response to IFN-beta therapy, and 
may provide an explanation of the lack of response to this therapy 
in some cases [96]. In particular, transient oscillatory dynamics 
could provide a way for the Stat1 pathway to increase the duration 
of its response to IFN-beta in a physiological manner (i.e. without 
a period of sustained constant activation as in fig. 36B). In order to 
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establish the conditions under which this transient dynamics 
exists, we analyzed the behavior of the system for combinations of 
two-parameter pairs, distinguishing between the parameter values 
for which pStat dynamics is overdamped (and thus non-
oscillatory) and those for which the oscillations are underdamped 
(which corresponds to the experimental situation reported above). 
We focused on the phosphorylation and dephosphorylation rates 
(bph and bdeph) and export and import rates (bexp and bimp). These 
parameters represent crucial steps to regulate the nuclear 
availability of transcription factors such as pStat dimers, and thus 
also the expression of downstream genes. 
 
Figure 37 Influence of activated receptor level on the transient oscillatory 
dynamics. (A). Time evolution of the activation level of type I IFN receptors 
in the model (S) by stimulation with IFN-beta (added at t = 0) for different 
initial levels (in red, S = 500 molecules at t = 0). (B, C) pStat1 (B) and Socs1 
mRNA (C) dynamic responses for varying levels of initial receptor activation 
as in panel A (lower lines in B and C correspond to lower lines in A). 
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In order to identify mathematically the two different 
dynamical regimes mentioned above, we examined the stability 
properties of the steady state of the ODE system for a constant 
activated receptor level (S) equal to its initial value. In that context, 
the underdamped/oscillatory regime is characterized by a steady 
state that takes the form of an unstable focus  (i.e. the stability 
eigenvalue with maximum real part has negative imaginary part), 
whereas the steady state in the overdamped/non-oscillatory 
regime is a node (the stability eigenvalue with maximum real part 
has no imaginary component). In that way, by calculating the 
imaginary part of the stability eigenvalue of the steady state with 
maximum real part, we can identify the parameter regions in 
which the pathway exhibits a transient oscillatory response to IFN-
beta. The result, for the parameter space formed by the 
phosphorylation and dephosphorylation rates bph and bdeph, is shown 
in fig. 37A. This figure shows, on the one hand, the prevalence of 
oscillations for a wide range of these parameters, and on the other 
hand it tells us the conditions for which transient oscillations exist. 
For instance, increasing sufficiently the dephosphorylation rate 
can transform an oscillatory regime into a non-oscillatory one, and 
reversely, by making the phosphorylation rate large enough the 
system can be made to exhibit transient oscillations. Figure 38B 
shows examples of these two dynamical regimes for two specific 
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parameter sets within this phase diagram. 
 
 
Figure 38 Stability analysis of the steady state solution in two 2D 
parameter spaces. (A, C) The color scale represents the absolute value of the 
imaginary part of the stability eigenvalue with maximum real part, 
corresponding to the steady state of the system after IFN stimulation, for 
varying phospho/ dephosphorylation rates (bph and bdeph, panel A), and 
nuclear export/import rates (bexp and bimp, panel B). Two distinct dynamic 
regimes can be identified with this analysis: the damped oscillatory regime 
(shifted to red) and the overdamped/ non-oscillatory regime (blue). (B, D) 
Examples of pStat1 time evolution in both regimes (damped and over-
damped in red/blue lines, respectively) corresponding to parameter position 
of circle markers for the two diagrams shown in panels A and B, respectively. 
 
 We also tested the influence of the import rate of pStat1 
molecules into the nucleus, and of the export rate of Stat1 from the 
nucleus into the cytosol. By tuning both parameters (bexp and bimp) 
simultaneously, we observed again that the transient oscillatory 
regime is prevalent in this system (fig. 38C). We found that the 
oscillatory regime is associated with high nuclear import rates in 
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combination with high export rates. For high export rates but low 
import rates, the pathway exhibits an overdamped (non-
oscillatory) response, showing a sustained plateau in the transient 
level of pStat1 (discontinuous blue line in fig. 38D). Conversely, for 
high import rates and low export rates the response is also 
overdamped, but with a faster decay (continuous blue line in fig. 
38D). We conclude that bifurcation analysis of the Stat1 pathway 
model identifies translocation to the nucleus as a critical step 
To check the hypothesis that nuclear translocation process is 
critical for the response to IFNbeta therapy in Multiple Sclerosis 
patients, we assessed Stat1 nuclear translocation after IFNbeta 
treatment in MS patients using ImageStreamX imaging platform 
(see methods). We adjusted the flow cytometry standard protocol 
using PBMCs from healthy controls (fig. 39).  
 
 
 
Figure 39 Nuclear translocation measured by ISX technology. UP: The 
example of nuclear localization of pStat1 visualized by ImageStreamX. 
DOWN: the quantification of PBMCs from a healthy control in vitro 
stimulated with 1000 un/ml of IFNbeta. Blue – the percent of pStat1+ cells 
from the total population, red – percent of pStat1+ cells with pStat1 localized 
in the nucleus from a total population of pStat1+ cells. 
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We obtained PBMCs from controls (n=2) and patients treated with 
IFNbeta (n=2) at different times after injection (fig. 39-40).  The 
PBMCs from controls were used for in vitro studies (fig. 39) The 
control in vitro stimulations of PBMCs from healthy individuals 
show very quick response with nearly all pStat1 translocating to 
the nucleus at 5 minutes and shuttling back in just 15 minutes after 
stimulation. 
 The PBMCs from MS patients were obtained in different 
time after the injection of IFNbeta (in vivo conditions). 
Figure 40 Nuclear translocation measured by ISX technology. The 
quantification of PBMCs from an MS patients treated with IFNbeta - Extavia 
(A and B) and Avonex (C and D). The time shows the time of blood 
withdrawal after injection. Blue: the percent of pStat1+ cells from the total 
population, Red: percent of pStat1+ cells with pStat1 localized in the nucleus 
from a total population of pStat1+  
The results from MS patients show significant differences in the 
nuclear translocation pattern between individuals. On fig. 40 in 
blue we see the percent of pStat1+ cells from the total number of 
cells at different times after in vivo injection. While for Extavia 
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patient this level stays nearly the same around 5-7%, the Avonex 
patient shows a sharp increase in pStat1+ PBMCs after 1-2 hours 
peaking at 17% and a slow decrease at 3-6 hours. The fig. 40B and 
40D shows the percent of translocated to the nucleus pStat1 in the 
Stat1+ cells in the same patients. While Extavia patient has a high 
level of nuclear Stat1 at a baseline and unexplainable decrease 
after the injection, the Avonex patient shows nearly no nuclear 
Stat1 at a baseline and quick translocation to up to 50% after 1-2 
hours post-injection with a decrease at later timepoints. 
While these results are promising, the sample size is too 
small to determine the translocation of Stat1 to the nucleus after in 
vivo injections of IFNbeta and a study with a bigger cohort of 
responders and non-responders to IFNbeta is needed to determine 
if pStat1 translocation rate can determine the response to therapy 
and serve as a clinical biomarker of the response.  
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Chapter 5. Nuclear translocation dynamics of Foxo3a 
orchestered by Sgk/Akt balance 
In order to model the Akt/Sgk-Foxo3a pathway (Foxo 
pathway), we have developed an ODE model based in previous 
knowledge and experimental data. The core feature of our model 
is the nuclear export and phosphorylation of pFoxo3a by pAkt and 
pSgk after activation of IGF1 pathway. The phosphorylation of 
Foxo3a in the 3 main phosphosites leads to its deactivation and 
arrest in the cytoplasm. Other post-translational modifications 
may lead to its ubiquitination and degradation (fig. 41).  
Our model shows the importance of the mechanism of 
inhibition of Foxo3a for the noise resistance of the system.  
In our model we consider following key points: 
• First mechanism: Activation of Akt (phosphorylation) by 
IGF1 or other growth factor leads to phosphorylation of Foxo3 in 3 
conserved sites. pFoxo3 transfers to the cytoplasm 
• Second mechanism: Sgk is activated either by PI3K pathway 
or by stress sensors and phosphorylates Foxo3a  
• pFoxo3a has three main phosphosites. pSgk and pAkt has 
different affinity to different pFoxo3a phosphosites but both lead 
to the phosphorylation of all three of them 
• Both mechanisms lead to export from the nucleus and 
inhibition of Foxo3a action as a TF 
• Dephosphorylation is induced by PP2A and allows Foxo3 to 
come back to the nucleus and bind specific binding sites restoring 
the pro-apoptosis gene expression pattern (this term should 
influence the kinetics of the system as well) 
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• Ubiquitination of Foxo3a targets it for degradation, which 
has influence in the kinetics of the system  
 
Figure 41 The model of Akt-Foxo3 signaling and Foxo3 nuclear 
shuttling 
The model is represented on the fig. 41 and consists of the 
following events and elements: IGF1 growth factor signal, 
phosphorylation and dephosphorylation of Sgk, phosphorylation 
and dephosphorylation of Akt, phosphorylation of Foxo3a in 3 
phosphosites by pSgk, phosphorylation of Foxo3a in 3 
phosphosites by pAkt, export of Foxo3a to the cytoplasm, 
dephosphorylation and import of pFoxo3a to the nucleus, 
activation of transcription of apoptotic genes by Foxo3a (non-
phosphotylated). We also included degradation of pFoxo3a, Akt 
and Sgk.  
On the top at the moment there are included several 
additional points: the negative regulation of pAkt by Pten (this 
includes inhibition of phosphorylation of pAkt by Pten) and active 
dephosphorylation of Foxo3a by PP2A 
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PTEN should be considered as a constant growing function 
and PP2A is considered to be constant for the moment 
The model can be represented as the following system of 
equations 
 
 where 
S is non-phosphorylated Sgk, Sp – phosphorylated Sgk, A - 
non-phosphorylated Akt, Ap – phosphorylated Akt, F - non-
phosphorylated Foxo3a, Fn_akt – phosphorylated in 3 phosphosites by 
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Akt Foxo3a in the nucleus, Fn_sgk – phosphorylated in 3 phosphosites  
by Sgk Foxo3a in the nucleus, Fc_akt – phosphorylated in 3 
phosphosites by Akt Foxo3a in the cytoplasm, Fn_sgk – 
phosphorylated in 3 phosphosites by Sgk Foxo3a in the nucleus, Fdc 
– nonphosphorylated Foxo3a in cytoplasm,  Fdn – 
nonphosphorylated Foxo3a in the nucleus, g – downstream genes, 
P - active PTEN molecules, D - active PP2A molecules 
The parameters are explained in the supplementary table 6.  
While this work is still in process we have preliminary 
promising results. From experimental perspective, we challenged 
the SH-Sy5 cell line with a new compound. The compound is in 
preclinical development as a potential drug for MS. We observed 
the oscillations in the nuclear translocation of Foxo3a during the 
first 2 hours after in vitro stimulation with the compound. The 
results were obtained by IHC.  
In order to understand this experimental observation we 
performed the analysis of the parameter space of our model and 
identified the set of parameters capable to produce oscillations 
with the same period. We are performing further experiments and 
simulations to validate the hypothesis of oscillatory behavior of 
the nuclear translocation of Foxo3a and its possible implication in 
drug discovery.  
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Discussion 
In this thesis I tried to assess the signal transduction 
molecular system in different levels of detail. Watching from 
hierarchical upper and lower levels I was able to identify different 
questions and examine the answers. As a result we examine 
several hypothesis from hierarchical perspective: 
1. The oscillatory dynamics of IL6 pathway in populations  
2. The connection between pathways in different cell lines 
(T cell and macrophage-like human cell lines) 
3. In-deep understanding of single pathway dynamics  
4. Exploration of a concrete dynamical feature: the 
translocation in two different pathways 
This top down approach brought us from general theoretical 
questions to possible clinical implication of Systems Biology.  In 
the discussion we’ll follow this logic from higher to lower 
hierarchy and compare the approaches and their outcomes. 
During the journey we developed new approaches and methods to 
combine Systems biology and Translational medicine and apply 
standard Systems biology approaches to clinical questions.  
Populations exhibit important dynamical features, which can 
be overwatched in traditional Systems biology dynamical 
approaches 
The behavior of populations and single-cell variability is a 
challenge for Systems biology approach with different methods 
developed to model the real populations  
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Different cell types provide different responses to external 
signals due to their network constructions 
In RAW cell line, Socs1 and IRF1 genes expression change 
during early IFN response, but there are no significant expression 
of some commonly used reference genes (Mx1 and OAS1a). Jak-
Stat pathway activation by IFN-beta activates the phosphorylation 
of Stat1, Stat2 and some other proteins. These activated proteins 
mainly form 2 different complexes: Stat1-Stat1 (AAF complex) and 
Stat1-Stat2-IRF9 (ISGF complex). Both complexes activate many 
genes in the nucleus binding to the specific regulation elements in 
the promoters. AAF complex binds to GAS elements and ISGF 
complex binds to ISRE elements. GAS-containing genes (Incl. 
Socs1 and IRF1) are responsible for the antibacterial response of 
the cells and ISRE-containing genes are activating an antiviral 
response of the cells [95]. Based on this background and our 
results we hypothesized that macrophages form mainly AAF 
complexes which activates the antibacterial route (GAS sequences) 
but in T cells the situation is opposite, activation ISFG3 elements 
and therefore the antiviral response (Figure 16). For example, it 
was recently shown that the response to IFN-beta differs between 
immune cells, and an analysis of non-responders to IFN-beta 
therapy indicates an impairment of the type I IFN pathway 
differentially in the monocytes of those patients [52]. 
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Figure 42 Possible explanation of the difference in RAW macrophages 
cell line IFNbeta signaling and classical Jak-Stat pathway.  
The IFN signaling network affects different complex 
pathways, involving processes such as differentiation, 
proliferation, survival and cell death. Importantly, it is a canonical 
pathway involved in different complex pathways, involving 
processes such as differentiation, proliferation or survival and cell 
death [97, 98] and also as a therapy for autoimmune [99]. IFN-beta 
is the most common treatment for MS [100], exerting a pleiotropic 
immunomodulatory activity not well understood. IFN-beta 
treatment decreases activation, proliferation, cytokine release, and 
migratory properties of activated T cells, diminishing their ability 
to enter and damage the brain tissue. In spite of these properties, 
up to 40% of patients do not respond to IFN-beta therapy, which 
represents a significant health problem [96]. Previous genomic 
studies have identified certain genes belonging to the IFN 
pathway that are associated with a lack of response to IFN-beta, 
suggesting that the genetic background of certain individuals may 
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modulate this pathway, and consequently the response to therapy, 
by specific transcriptional profiles [101].  
This considerations led us to the idea of studying the 
difference in type I and type II IFN signaling in macrophages and 
T cells. We chose the Boolean modeling approach to be able to 
explore more extended networks. We found significant differences 
between 2 networks including differences in IFNbeta-Stat1-Stat2 
connections and IFNgamma-Stat1-Stat2 connections we expected 
from our hypothesis of Stat1-Stat2 and Stat1-Stat2 dimers 
formation theory explained above.  
In-depth understanding of IFNbeta signaling pathway 
dynamics in RAW 264.7 macrophage-like cell line 
We analyzed the type I IFN-beta signaling pathway in 
macrophages, showing that the response of this pathway to IFN-
beta stimulation takes the form of transient oscillations in Stat1 
phosphorylation. We characterized and identified the critical 
elements governing the transient dynamics of IFN activation, and 
examined the influence of this dynamical regime in the response to 
IFN-beta. To that end, we quantified in a time-resolved manner the 
level of certain pathway components after IFN-beta activation, and 
implemented a mathematical model of the Jak/Stat pathway. 
Dynamical models of IFN induction of the Jak/Stat signaling 
pathway based on nonlinear ordinary differential equations, have 
been previously used to study the effect of IFN pre-treatment on 
the response of the immune system to virus infection [44, 45] and 
the robustness of the pathway to noise and parameter fluctuations 
[46], among other problems. Systems biology approaches have also 
been applied to this pathway in order to examine its role in certain 
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pathological mechanisms underlying the behavior of cancer cells 
[102], and its interaction with other key signaling pathways [44, 
103]. Here we combine our theoretical model with experimental 
observations, in order to study the role of the pathway architecture 
on the immediate molecular response of the pathway to IFN-beta 
stimulation. Our results show that a combination of positive and 
negative feedback loops, together with the eventual degradation of 
the IFN signal in the medium, leads to a transient oscillatory 
response in several components of the pathway. This behavior is 
consistent with previous numerical results found in pure modeling 
studies [104], and goes beyond previous observations that indicate 
a simpler transient response [37, 85, 98]. We interpret the transient 
oscillatory response of the pathway in terms of the potential 
effectiveness of IFN-beta treatment in MS patients. 
Jak-Stat signaling pathway regulation appears to be more 
complex than it was thought before. It is tightly regulated and 
highly connected with other pathways [105]. Moreover, type I 
IFNs are commonly used as treatment in several chronic diseases 
such as hepatitis C, leukemia and Multiple Sclerosis (MS). 
Improving our understanding on how this signaling pathway 
works, processes information and participates in the pathogenesis 
of these diseases or in the response to therapy would improve our 
ability to manage such diseases.  
One of the aims of this work was to characterize the 
dynamics of the key components of the type I IFN-beta signaling 
pathway in macrophage RAW 264.7 cells. This system robustly 
translates extracellular chemical signals through cell membrane 
receptors, leading to phosphorylation of the Stat transcription 
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factors, which induce gene expression of multiple targets. Jak/Stat 
signaling directly regulates the immune system response under 
viral or bacterial infection, and is also important in autoimmune 
diseases and cancer treatments. The IFN signaling network affects 
different complex pathways, involving processes such as 
differentiation, proliferation, survival and cell death. Importantly, 
it is a canonical pathway involved in first-line treatments of 
multiple sclerosis as a main target of the IFN system [99] but, also, 
affects different complex pathways, involving processes such as 
differentiation, proliferation or survival and cell death [90, 91].  
Our IFNbeta model simulations exhibit a transient oscillatory 
behavior in pStat1 concentration, and reveal that the oscillations 
require the presence of a negative feedback loop on Stat1, 
mediated by its phosphorylation inhibitor Socs1. Previous 
mathematical models of the type I and type II IFN pathways have 
suggested the possibility that Stat1 pathway has an oscillatory 
behavior [36, 97] and indicated the importance of the Socs1 
negative feedback [85, 100]. Another factor that has been proposed 
to be important in defining the response to IFN is the basal level of 
receptors of the Jak/Stat pathway[106]. In our model this aspect 
was also taken into account, showing clear effects on the dynamics 
of the pathway response. Going beyond previous models, our 
theoretical results show that the physiological regime of the 
pathway’s response to IFN-beta takes the form of damped 
oscillations that can be identified by means of a stability analysis of 
the model’s steady state solution. This analysis shows that 
processes such as the phosphorylation and dephosphorylation of 
pStat1, and the transport of Stat1 between the nuclear and cytosol 
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compartments, can make the pathway switch between 
underdamped and overdamped oscillatory regimes [107]. 
Limitations 
There are several limitations in this research. 
From the experimental point of view we used cell lines in 
most of our studies. Cell lines is a simple and powerful tool to 
explore signaling pathway dynamics but may differ significantly 
from in vivo conditions. For the validation of the translocation of 
Stat1 as a potential biomarker we used PBMCs from MS patients in 
a small cohort. The clinical findings have to be validated on a 
much bigger cohort of patients. The design of the in vivo study 
doesn’t allow the comparison with healthy controls and patients 
due to injection of a prescribed drug.  
For Boolean modeling we used al limited phosphoproteins 
dataset so we couldn’t see some of the possibly presented links 
due to the lack of the clinical data. 
The main limitation of the ODE modeling is the unknown 
parameters in most of the cases. Many parameters con’t be derived 
from the experimental or don’t have direct biological meaning. We 
overcome this limitation by comparing our model to experimental 
data but can’t reject possible biases due to manual parameter fit. 
Sgk/Akt-Foxo3a model lack experimental validation, which 
is the next step planned in this project and should be available 
soon.  
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Implications of the type I IFN and Sgk/Akt-Foxo3a signaling 
dynamics in autoimmune diseases 
IFN-beta is the most common treatment for MS [100], 
exerting a pleiotropic immunomodulatory activity not well 
understood [99]. IFN-beta treatment decreases activation, 
proliferation, cytokine release, and migratory properties of 
activated T cells, diminishing their ability to enter and damage the 
brain tissue. In spite of these properties, up to 40% of patients do 
not respond to IFN-beta therapy, which represents a significant 
health problem [96]. Previous genomic studies have identified 
certain genes belonging to the IFN pathway that are associated 
with a lack of response to IFN-beta, suggesting that the genetic 
background of certain individuals may modulate this pathway, 
and consequently the response to therapy, by specific 
transcriptional profiles [101]. For example, it was recently shown 
that the response to IFN-beta differs between immune cells, and an 
analysis of non-responders to IFN-beta therapy indicates an 
impairment of the type I IFN pathway in the monocytes of those 
patients [52][108]. 
Our study indicates the importance of identifying the 
temporal dynamics of the concentration of certain key components 
of the Jak-Stat pathway, such as the phosphorylated form of the 
Stat1 protein, and of the expression of interferon-stimulated 
transcription genes like Socs1 and IRF1, within the first 8 hours of 
IFN-beta administration. Cataloguing these dynamics could 
provide us with early molecular biomarkers that allow us to 
distinguish the lack of response to IFN-beta therapy of certain MS 
patients. 
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Our models indicate the crucial role of nuclear translocation 
of Stat1 and Foxo3a molecules for the correct dynamics of the 
whole pathway. The alterations in the translocation features of 
Stat1 prevail over the rates of phosphorylation and 
dephosphorylation in determining the oscillatory dynamics of 
IFNbeta signaling pathway. On a small group of MS patients we 
showed that the rate of translocation differs a lot between 
individuals and may determine the response to therapy or disease 
progression. The levels of Stat1 translocation may be potential 
biomarkers of IFNbeta treatment response and require further 
research.  
Another example of the importance of nuclear shuttling 
characteristics in signal transduction is Foxo3a transcription factor. 
Foxo3a can be considered as a master regulator of the PI3K-Akt 
pathway, which determines the survival or apoptotic scenario of 
cell decision [109]. In this case the quality and versatility of the 
network structure (inhibition by phosphorylation in the nucleus 
and further transfer to the cytosol) as well as the numerous 
possible post-transcriptional modifications [56] make Foxo3a an 
example of the key node protein tightly regulated to prevent 
misconducted decisions of the cell. The model of Akt-Foxo3a 
signaling is an interesting tool from both theoretical and practical 
point of view. From the theoretical side, the Akt-Foxo3a signaling 
is an example of a larger group of signal transduction pathways 
involved in cell decisions, which share number of common 
patterns of behavior. The kinetics of Akt-Foxo3a and its regulation 
and crosstalk may be a common trend in the whole class of 
signaling pathways. The reason for the phosphorylation- 
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inhibition-nuclear export structure is the resistance to noise of such 
mechanism of action and easy tuning possibilities and constantly 
changing behavior. 
From the practical point of view, Foxo3a is an emerging 
target in immunology and neurology [65, 110]. The new promising 
neuroprotective drug for MS BN201 targets Sgk, the upstream 
kinase of Foxo3a, and modifies Foxo3a activity. The understanding 
of the Sgk-Akt balance and communication as well as Foxo3a 
behavior in human cells in different conditions let us predict the 
effects of the new emerging treatments of MS. 
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Conclusions 
1. The population of cells has an ability to coordinate 
and synchronize their activity in response to IL-6 stimulation. This 
ability is a necessary attribute of the cell signaling, which allows 
correct response to the external systems and provides a more 
robust response to the environment. 
2. T cells and macrophages respond different to 
IFNbeta, IFNgamma or infectious agents due to the qualitative 
difference in their signaling networks. These differences lead to a 
complex repertoire of behaviors of immune system cells in 
response to different challenges as well as to the response to 
IFNbeta treatment in autoimmune diseases. 
3. The IFN-beta signaling in macrophages takes the 
form of transient oscillatory dynamics of the Jak-Stat pathway, 
whose specific relaxation properties determine the lifetime of the 
cellular response to the cytokine, which has implication for the 
outcome of the immune response. 
4. The nuclear translocation of pStat1 modulates the 
dynamics of Jak-Stat signaling system and leads to the switch 
between damped/overdamped oscillatory regimes. Individuals 
with different clinical response to IFNbeta therapy showed 
differences in the dynamics of nuclear translocation of pStat1, 
becoming a promising biomarker for monitoring the response to 
this therapy.  
5. The inhibition through phosphorylation of pFoxo3a 
is a molecular switch, which allows tighter regulation of the 
Foxo3a transcriptional activity. Nuclear shuttling of Foxo3a is a 
kinetic buffer of Foxo3 activity and keeps the equilibrium between 
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survival and tumor repression mechanism. This Foxo3a switch 
mechanism is controlled by the coordinated activation of Akt and 
Sgk in the PI3K pathway. 
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Supplementary data 
Supplementary Table 1. Parameters for Stat3 ODE model [units/ 
cell]  
Name Sym
bol 
V
alue 
Unit
y 
Active IL6 receptors             
S 
[0
-500] 
# 
Transcription rate for Socs3 br 1
1.3 
min-1 
Translation rate for Socs3 bR 1.
0·102 
min-1 
Phosphorylation Stat3 rate bph [4
0-80] 
min-1 
Dephosphorylation Stat3 
rate 
bdeph 0.
1 
min-1 
Import to the nucleus rate 
(pStat3) 
bimp 0.
03 
min-1 
Export from the nucleus rate 
(Stat3) 
bexp 0.
09 
min-1 
Dephosphorylation Stat3 
rate in nucleus 
bdeph_nucleus 0.
046 
min-1 
Stat3 phosphorylation 
activation  
(Hill’s constant; half 
maximal activation) 
kA 1
7040 
mole
cules 
Dissociation constant for the 
enzyme-inhibitor by Socs3 (Hill’s 
constant; half maximal activation) 
kI 8
2680 
mole
cules 
Socs3 transcription 
activation by nuclear pStat1 (Hill’s 
constant; half maximal activation) 
kr 3
4000 
mole
cules 
Cooperativity of Socs1 
protein over Stat1 dimers 
q 4  
Cooperativity of Stat1 on 
Socs1 gene promoter 
n 4  
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Socs1 RNA degradation rate λr 0.
02 
min-1 
Socs1 protein degradation 
rate 
λR 0.
017 
min-
1 
Stat1 protein degradation 
rate 
λStat  1.
0·10-5 
min-1 
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Supplementary table 2. Initial conditions for Stat3 model 
simulations 
Name Sy
mbol 
          Value 
IL6 active receptors S 600-700 
molecules 
U-phosphorylated cytoplasmic 
Stat3  
Ac 7.5·104 
molecules 
Phosphorylated cytoplasmic 
Stat3  
Ap
c 
1 molecule 
Phosphorylated nuclear Stat3 Ap
n 
1 molecule 
U-Phosphorylated nuclear Stat3  An 2.5·104 
molecules 
Socs3 mRNA r 1 molecule 
Socs3 protein R 1 molecule 
 
Supplementary table 3. Parameters for type I IFN ODE model  
N
am
e 
S
y
m
b
ol
 V
al
u
e 
U
n
it
 
Translation rate for Stat1  bA 65 min-1 
Receptor production 
rate 
bS 0 min-1 
Basal Stat1 RNA BStat1 0.0062 min-1 
Transcription rate for 
Stat1  
ba 0.1 min-1 
Transcription rate for 
Socs1 
br 12.8 min-1 
Transcription rate for 
IRF1 
bf 2.7 min-1 
Translation rate for IRF1 bF 1.0·101 min-1 
Translation rate for 
Socs1 
bR 1.0·102 min-1 
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Phosphorylation Stat1 
rate 
bph 1.3·103 min-1 
Dephosphorylation 
Stat1 rate 
bdeph 0.036 min-1 
Import to the nucleus 
rate (pStat1) 
bimp 0.013 min-1 
Export from the nucleus 
rate (Stat1) 
bexp 0.048 min-1 
Stat1 phosphorylation 
activation  
(Hill’s constant; half 
maximal activation) 
kA 4680 molec
ules 
Dissociation constant for 
the enzyme-inhibitor by Socs1 
(Hill’s constant; half maximal 
activation) 
kI 82680 molec
ules 
Socs1 transcription 
activation by nuclear pStat1 
(Hill’s constant; half maximal 
activation) 
kr 23400 molec
ules 
IRF1 transcriptional 
activation by pStat1  
kf 7366 molec
ules 
Stat1 transcriptional 
activation by IRF1 
kF 1.3·105 molec
ules 
Cooperativity of Socs1 
protein over Stat1 dimers 
q 4  
Cooperativity of Stat1 
on Socs1 gene promoter 
n 3  
Cooperativity of Stat1 
on IRF1 gene promoter 
m 2  
Cooperativity of IRF1 on 
Stat1 gene promoter 
u 1  
Receptor 
internalization/degradation 
rate 
λS 0.0229 min-1 
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Socs1 RNA degradation 
rate 
λr 0.0347 min-1 
Socs1 protein 
degradation rate 
λR 0.0231 min-1 
IRF1 RNA degradation 
rate 
λf 0.0173 min-1 
IRF1 protein 
degradation rate 
λF 0.0116 min-1 
Stat1 RNA degradation 
rate 
λa 0.0058 min-1 
Stat1 protein 
degradation rate 
λStat  0.0007 min-1 
 
 
Supplementary table 4. Initial conditions for type I IFN ODE 
model simulations 
N
a
m
e 
S
y
m
b
ol
 V
a
lu
e 
Non-phosphorylated Stat1 A 1.0·105 
molecules 
IFN activation receptor S 1000 molecules 
Phosphorylated nuclear Stat1  Apn 1 molecule 
Phosphorylated cytoplasmic 
Stat1  
Apc 10 molecules 
Stat1 mRNA a 1 molecule 
IRF1 mRNA f 1 molecule 
Socs1 mRNA r 1 molecule 
IRF1 protein F 1 molecules 
Socs1 protein R 1 molecule 
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Supplementary table 5. Initial conditions for Foxo3a model 
dynamics exploration  
I 1*105-1*106 
P 1*105 
A 1*105 
Fdc 1000 
S 1*105 
Ap 0 
Sp 0 
Fn_akt 0 
Fc_akt 0 
Fn_sgk 0 
Fc_sgk 0 
D 5*106 
 
Supplementary table 6. Parameters for Foxo3a model 
dynamics exploration (adopted from [111])  
Sy
mbol  
Biological and mathematical 
explanation 
fixed parameters 
r1 dephosphorylation rate of Sgk  
ksp phosphorylation rate of Sgk 0,055 
I number of signal molecules  
ks Hill’s coefficient  
r10 dephosphorylation rate of Akt 0,5 
kap phosphorylation rate of Akt  
kA Hill’s coefficient  
kexp Foxo3a export from the nucleus to 
the cytoplasm  
 
kimp Foxo3a import from the cytoplasm to 
the nucleus 
0,182 
r8 Foxo3a degradation rate  0,1 
ka rate of phosphorylation of Foxo3a by 
pAkt 
0,5 
kf Hill’s coefficient  
kdeph dephosphorylation rate of Foxo3a 1 × 10-6 
ks rate of phosphorylation of Foxo3a by 
pSgk 
 
kg target gene transcription rate 0,95 
ke Hill’s coefficient  
r18 target gene degradation rate  
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λS degradation rate of Sgk  
λA degradation rate of Akt  
n Cooperativity of the activation of Sgk  
m Cooperativity of the activation of Akt  
j Cooperativity of the pAkt on the 
Foxo3a phosphosites 
6 
q Cooperativity of the pSgk on the 
Foxo3a phosphosites 
 
t Cooperativity of Foxo3a on the 
promoter of the target gene 
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Resumen en castellano 
Modelos de vías de señalización de citoquinas para el 
estudio de enfermedades autoinmunes 
Resumen 
La biología de sistemas abre nuevas fronteras en el estudio de 
enfermedades complejas como la Esclerosis Múltiple (EM). Las preguntas que 
era imposible contestar antes por falta de entendimiento y de una base 
metodológica adecuada, tales como el mecanismo molecular de acción de 
múltiples fármacos en las vías de señalización, son resueltas ahora mediante el 
uso del punto de vista de la Biología de Sistemas. Dichas vías de señalización 
tienen tanto un componente matemático como un componente biológico. La 
Biología de Sistemas moderna ha desarrollado diversos métodos para modelar 
las vías de señalización y predecir sus comportamientos en diferentes 
condiciones. 
Esta disertación se centra en algunos de los mecanismos moleculares 
clave en la transducción de señales durante el desarrollo y la progresión de la 
EM, elementos clave para lograr explicar el mecanismo de acción de los 
fármacos más usados en la EM. 
Mis principales hipótesis se basan en la presunción de que el principio 
más relevante de los sistemas biológicos son las conexiones entre las moléculas 
en lugar de las moléculas per se (p.e.: los bordes en lugar de los nodos en los 
modelos gráficos). Un ejemplo de esto se encuentra en los subtipos de células 
inmunes, que tienen distintas respuestas a los estímulos externos dado que 
interactúan entre ellas dentro de las células más que por sus componentes sean 
distintos. Otros ejemplos de esto son las cargas cinéticas conducidas por los 
cambios en la actividad tanslocalizadora de la proteína Stat1. 
Para probar mi hipótesis, he desarrollado dos modelos matemáticos 
distintos de la vía de señalización de IFNbeta: Booleano y ODE. La combinación 
de los dos modelos nos permite observar la vía de señalización desde dos 
puntos de vista distintos: en conexión con otras vías de señalización 
relacionadas y como un sistema cinético.  
Hemos detectado regímenes oscilatorios en la señalización de IFNbeta y 
sus parámetros clave, que determinan los cambios en los regímenes. Ambos 
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modeles fueron validados experimentalmente y nos condujeron a diversas 
predicciones que podrían ser clave para el desarrollo de nuevos fármacos o 
combinaciones de fármacos. Por ejemplo, el análisis de bifurcación del modelo 
cinético reveló la importancia de las propiedades de la translocación nuclear de 
la proteína Stat1 para el correcto funcionamiento de la vía de señalización. 
La translocación nuclear es un elemento clave conocido de este sistema 
pero nos focalizamos en los circuitos de conexión y desconexión y la 
importancia de la combinación de diferentes lugares de fosforilación para la 
transducción de señales. 
Los principales resultados de este trabajo son: 
1. Nuevos modelos de vías de señalización de IFNbeta y Akt/Sgk 
2. Predicción de prevalencia de los parámetros de translocación 
sobre las tasas de fosforilación de la vía de señalización IFNbeta 
3. Un nuevo método de aplicación del modelo Booleano a datos 
clínicos 
Concluyendo, la Biología de Sistemas es una herramienta poderosa para 
predecir nuevas propiedades de sistemas biológicos, que pueden ser usados en 
la práctica clínica, como biomarcadores dinámicos o señales de transducción 
diferenciales. 
Introducción 
Las vías de señalización en las enfermedades autoinmunes 
Las moléculas extracelulares, como las citoquinas, juegan un rol crucial en 
la transducción de señales. Una de las vías de señalización prototípicas más 
estudiadas es la del interferón tipo I. Ésta es una vía de señalización conducida 
por señales Jak-Stat. Los interferones tipo I (IFNalfa e IFNbeta) se combinan con 
el mismo receptor, llamado IFNAR y activan la vía de señalización Jak-Stat: Los 
IFNs tipo I se combinan con receptores IFNAR1, la fosforilación de las proteínas 
Jak1 y TYK2 transmiten la señal, la fosforilación de las proteínas Stat1 y Stat2 
permite la formación del compuesto ISGF3 (pStat1-pStat2-IRF9) que se combina 
con los receptores ISRE en el núcleo. Se probó que al mismo tiempo que el 
compuesto ISGF3 se forma, su estimulación también forma otros factores de 
transcripción que contienen Stat1 activado. El principal de ellos es GAF 
(homodimero Stat1-Stat1), el principal compuesto para la vía de señalización 
IFN tipo II (fig. 1). Existen distintas moléculas activadoras e inhibidoras, que 
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regulan la fosforilación de tirosina de Stat1. Su expresión se regula mediante el 
factor de transcripción GAF (pStat1-pStat1) al enlazarse con elementos GAS, que 
son presentados en el promotor Socs1. 
Dado que los interferones tipo I juegan un rol clave en la inmunidad 
innata y adaptativa, son usados frecuentemente como una terapia en el 
tratamiento de la EM. Interpretamos la respuesta transiente oscilatoria de la vía 
de señalización para evaluar la efectividad potencial del tratamiento con IFN-
beta en pacientes con EM. 
Aproximaciones a los modelos en biomedicina 
Los modelos dinámicos de inducción de IFN en la vía de señalización 
Jak/Stat basados en ecuaciones diferenciales ordinarias no lineares han sido 
usados previamente para estudiar el efecto del pre tratamiento con IFN en la 
respuesta del sistema inmune a la infección vírica [1][2] y la robustez de la vía 
de la señalización frente al ruido y las fluctuaciones de parámetros [3] entre 
otros problemas. Las aproximaciones a través de la Biología de Sistemas 
también han sido aplicadas a esta vía de señalización para estudiar su rol en 
ciertos mecanismos patológicos subyacentes en el comportamiento de las células 
cancerígenas [4] y su interacción con otras vías de señalización clave [1][5]. 
Estudios anteriores sugieren una combinación de espirales de feedback 
positivas y negativas, junto con la eventual degradación de la señal de IFN en el 
médium, lo que lleva a una respuesta transitiva oscilatoria en diversos 
componentes de la vía de señalización. Este comportamiento es constante con 
anteriores resultados numéricos encontrados en modelos puros [6], y va más 
allá de observaciones previas que indicaban una respuesta transitiva simple 
[3][7][8]. 
La regulación de la vía de señalización Jak-Stat parece ser más compleja 
de lo que se suponía previamente. Esta íntimamente regulada y conectada a 
través de otras vías de señalización [9]. Los IFNs de tipo 1 son usados 
comúnmente como tratamiento en diversas enfermedades crónicas como la 
hepatitis C, la leucemia y la EM. Mejorar nuestro entendimiento sobre el 
funcionamiento de esta vía de señalización, su procesamiento de información y 
su participación en la patogénesis de estas enfermedades o en sus respuestas a 
las distintas terapias mejoraría nuestra capacidad de gestionar dichas 
enfermedades. 
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Otra vía de señalización crítica bien conocida para factores de 
señalización tróficos es PI3K. La vía de señalización PI3K-Akt es clave en la 
apoptosis que juega un papel clave en la longevidad y el cáncer. Es activada 
mediante factores de crecimiento como el Factor de Crecimiento de Insulina 
IGF1. IGF1 se enlaza con el dominio externo de los receptores RTK. La 
fosforilación del dominio interno del receptor conlleva el enlace de PI3K. Una 
vez activado, PI3K se enlaza con el fosfolípido de membrana PIP2, 
transformándolo en su forma activada PIP3. PIP3 activa la vía de señalización 
Akt mediante su fosforilación. pAkt activa muchos procesos celulares distintos 
promoviendo el crecimiento celular y previniendo la muerte celular. El principal 
mecanismo de PI3K-Akt es la activación de la síntesis de proteína mTOR y su 
translación. El otro mecanismo es la inhibición de la actividad apoptótica de 
Foxo3 mediante su fosforilación. 
La vía de señalización PI3K-Akt es crítica para los factores de crecimiento 
que promueven la supervivencia celular a través de la fosforilación de Foxo3. En 
esta vía, la translocación nuclear de Foxo3 después de su fosforilación es un 
paso clave para modular la expresión genética. La familia de factores de 
transcripción (TFs) Foxo (Forkhead Box, type O) causan cambios en la expresión 
génica, implementando un programa de respuesta al estrés celular, y un 
incremento en su actividad lleva a las intervenciones genéticas que extienden la 
longevidad en modelos de organismos. Foxo se conserva en todos los animales, 
desde los gusanos a los humanos. La fosforilación de proteínas Foxo en 
respuesta a los factores de crecimiento como IGF-I, eritropoyetina, factor de 
crecimiento de la epidermis o el factor de crecimiento de nervios causa la 
exclusión del núcleo [10]. Para muchas quinasas proteicas activadas por factores 
de crecimiento, los lugares específicos de fosforilación son conocidos. Éstas 
incluyen Akt y serum y quinasa inducible glucocorticoide (Sgk), que son 
activadas principalmente a través de la vía de señalización PI3K [11][12]. La 
fosforilación de Foxos en respuesta al estrés oxidativo envuelve a JNK y resulta 
en la importación de Foxo en el núcleo. 
Objetivos 
El objetivo general de la tesis es desarrollar un método para modelar vías 
de señalización y mejorar el entendimiento sobre como la información se 
transmite a través de ellas. Un objetivo secundario es usar estas vías para la 
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investigación traslacional, para lograr entender como los fármacos apuntan a 
estas vías e identificar biomarcadores sobre la respuesta a la terapia. Los 
objetivos específicos son: 
 
1. Construir, validar y comparar redes Booleanas de vías de 
señalización de IFN en células T y macrófagos usando líneas celulares humanas 
2. Desarrollar un modelo cinético de la vía de señalización de IFN 
tipo I y validarlo mediante datos experimentales obtenidos con líneas celulares 
de macrófagos de ratones 
3. Evaluar el papel de la traslación nuclear de Stat1 en la cinética 
de las vías de señalización, sus dinámicas y como responden a estímulos 
4. Desarrollar un modelo cinético de la vía de señalización Akt-
Foxo3a y validarla usando datos obtenidos mediante la experimentación 
Materiales y métodos 
Líneas celulares y muestras de sangre: 
Usamos la línea celular RAW 264.7 para obtener datos experimentales 
para la validación del modelo ODE. Para el modelo Booleano usamos líneas 
celulares Jurkat y humanas obtenidas de un banco de células ATCC. Los PBMCs 
de controles sanos fueron obtenidos en el Hospital Clínico de Barcelona. 
ELISA y citometría de flujo: 
Usamos la técnica de ELISA para medir la concentración de IFNbeta en el 
medio. Usamos ELISA intra celular para analizar las concentraciones de 
proteínas SOCS1 durante LPS y la estimulación mediante IFNbeta de células 
RAW en cultivos. 
qRT-PCR: 
Para medir los niveles de SOCS1 en mRNA usamos RT-PCR, y para 
validar los resultados de la citometría de flujo y ELISA usamos la técnica 
western blot estándar. 
ImageStreamX imaging system: Para determinar la cantidad de pStat1 
transportándose hasta el núcleo tras la inyección de IFNbeta en pacientes con 
EM utilizamos el sistema de imagen ImageStreamX que permite la visualización 
de la colocación de dos moléculas distintas usando anticuerpos conjugados con 
fluorocromo. Los núcleos fueron etiquetados con DAPI y Stat1 con anticuerpo 
anti humano de ratón Alexa Flúor 488 pStat1 (Y701). 
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Modelo ODE: 
El modelo y las simulaciones fueron diseñados en MATLAB utilizando el 
solucionador ODE15s (el código de Matlab es proporcionado en el material 
suplementario). El análisis de estabilidad del sistema dinámico fue realizado a 
través de códigos Matlab hechos a medida. 
Modelo Booleano: 
La red de conocimiento previa (PKN) fue construida usando data-mining 
y bases de datos existentes. Convertimos nuestros datos al formato MIDAS 
aceptado por datarail y describimos PKN en un fichero sif que puede ser 
visualizado usando Cytoscape. Utilizamos software CNOptR para encajar el 
modelo con los datos experimentales. Todos los scripts y las funciones fueron 
escritas en R. El paquete CellNoptR y otros fueron descargados de 
Bioconductor. Graphviz y Cytoscape fueron usados para la visualización de los 
modelos. 
Resultados 
Capítulo 1. Consideraciones teoréticas sobre las dinámicas de vías de 
señalización en células individuales y poblaciones de células 
Desarrollamos un modelo ODE de la vía de señalización IL6, que muestra 
las siguientes características: i) el modelo lleva por su propia naturaleza a un 
límite estable de ciclos con perfiles de periodos y fases que encajan con los 
valores observados experimentalmente; (ii) el límite de ciclos cuenta con un 
periodo pronunciadamente robusto para un largo rango de valores de 
parámetros, como la cantidad de citoquinas y el total de proteínas Stat; (iii) la 
estimulación de la vía de señalización mediante la adición súbita de inductor 
lleva a la sincronización de la población de células que ya estaban oscilando de 
manera dosis-dependiente. 
 Para entender mejor la naturaleza de la distribución calculamos el 
coeficiente de variación (CV) de los datos de citometría de un flujo celular único. 
CV se calcula como la desviación estándar dividida por la mediana para cada 
punto de tiempo medido. CV es la medida de la diferencia en la respuesta de las 
células a un estímulo en el mismo punto en el tiempo. Muestra que la 
desincronización de las células ocurre 15 minutos después de la estimulación. 
Todas las células son activadas al mismo tiempo, pero en distintos niveles 
(amplitud de respuesta). Entonces CV decrece para remontar de nuevo. El 
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segundo mínimo de CV en el minuto 200 corresponde al segundo pico de la 
respuesta mediana. Eso implica que las células ganan una mayor sincronía en el 
segundo pico que en el primero. Tras el segundo pico las células se de-
sincronizan de nuevo y vuelven a un estado estable. La cinética permanece igual 
con distintas concentraciones de IL6. 
En términos biológicos, la segunda ronda de activación celular 
corresponde en gran medida a la sincronización celular y a la actividad de la 
población como un sistema completo más que como células diferentes con 
respuestas individuales. Puede ser de importancia para generar la correcta 
respuesta inmune. 
Capítulo 2. Modelo booleano de la vía de señalización IFNbeta en 
humanos 
La vía de señalización IFNbeta interactúa con muchas vías de 
señalización virales y antibacteriales, convirtiéndose en parte de una red mayor. 
Hemos desarrollado una topología simplificada de dichas interacciones llamada 
la Red de Conocimiento Preliminar (PKN) en nuestro estudio. En esta PKN 
hemos etiquetado los estímulos, los mediadores y los genes así como las 
espirales de feedback y la comunicación entre las distintas vías de señalización 
en la red. El propósito del modelo Booleano es predecir nuevas interacciones 
entre las moléculas en la red. Resumiendo, nuestro objetivo ha sido el de 
construir redes celulares específicas de IFNs de tipo I y vías de señalización en 
células T y macrófagos. Usamos las células T y las líneas celulares similares a los 
macrófagos (Jurkat y THP1) para obtener los datos experimentales. Las células 
fueron testadas entonces con combinaciones de distintos estímulos e inhibidores 
y distintas fosfoproteínas, que fueron medidas a través de ensayos XMAP bead 
en estas condiciones. 
Los datos obtenidos de las líneas celulares y la adecuación del modelo son 
mostrados en las figuras suplementarias 1 y 2. Tras aplicar el algoritmo 
CellNoptR a PKN y los datos experimentales de dos líneas celulares distintas, 
obtuvimos los modelos lógicos y topológicos para cada línea celular. Los 
modelos pueden ser representados como scaffolds (fig. 1) que permiten evaluar 
las diferencias de señalización entre las líneas celulares Jurkat y THP1. 
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Figura 1. Scaffolds obtenidos desde modelos lógicos para las líneas 
celulares Jurkat (arriba) y THP1 (abajo) 
Dado que muchas de las principales vías de señalización son las mismas 
(lo cual puede esperarse dada la cercana relación entre todos los subtipos de 
células inmunes), hay claras diferencias entre los dos andamiajes. Mientras que 
en THP1 la conexión IFNbeta-Jak1-Stat2 es directa, en Jurkat Jak1 no está 
directamente activando Stat2. En este caso la activación viene dada por otros 
intermediarios. También, en THP1 vemos que la activación de CREB viene 
promovida por IFNbeta, mient4ras que en Jurkat no se aprecia este efecto. Hay 
otras diferencias en la señalización que podrían explicar algunas de las 
diferencias en la respuesta de los subtipos de células inmunes in vivo (ver la 
discusión). 
La diferencia en la vía de señalización IFN tipo I entre los subtipos de las 
células inmunes puede ser crucial para la respuesta celular al tratamiento con 
IFNbeta. Por esta razón hemos desarrollado un método para aplicar el mismo 
acercamiento hacia los datos clínicos de pacientes individuales. El reto de los 
datos clínicos radica en la diversidad entre individuos en la cohorte, lo que 
produce ruido en los datos. Por este motivo hemos propuesto los siguientes 
algoritmos para el análisis de las lecturas homogéneas de dos grupos de 
individuos. Aplicamos el paquete CellNoptR a los resultados estimulados de los 
experimentos, imitando los datos de los pacientes [13]. PKN y los datos 
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simulados fueron utilizados entonces para la optimización del método de 
promedio y comparación las redes topológicas resultantes. El método fue 
utilizado para promediar cadenas de bits correspondientes a cada modelo 
generado de cada set de datos. 
Capítulo 3. Modelo matemático IFN-beta 
Para identificar los elementos críticos de la vía de señalización 
responsables del comportamiento transitorio oscilatorio observado 
experimentalmente en macrófagos durante la estimulación con IFN-beta, 
construimos un modelo ODE basado en conocimiento biológico y datos 
experimentales (Fig. 2). Para minimizar su complejidad, hemos perseguido el 
sistema mínimo que explique las observaciones experimentales, en lugar de un 
sistema descriptivo completo [7]. 
 
 
Figura 2. Representación gráfica del modelo matemático de la vía de 
señalización IFN tipo I 
Hemos construido un sistema dinámico de la vía de señalización IFN-beta 
usando datos experimentales de proteínas y mediciones de concentraciones de 
mRNA in vitro y conocimiento biológico previo. El modelo esta basado en 
ecuaciones diferenciales ordinarias (ODE) y predice el comportamiento de la vía 
de señalización IFN-beta durante el tiempo. El modelo simple incluye las partes 
principales y más importantes de la vía, como la fosforilación de Stat1, la 
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inhibición la fosforilación de Stat1 y otras. El modelo se centró en los eventos 
auto-regulatorios de la vía. Verificamos los modelos mediante los experimentos 
con líneas celulares murinas RAW similares a macrófagos. 
Las ecuaciones diferenciales ordinarias para el modelo mostrado en fig.2 
son: 
 
 
 
Usamos diversos métodos para obtener los parámetros del modelo. 
Algunos de los parámetros fueron estimados utilizando datos experimentales 
provenientes de conocimiento previo mientras que otros fueron encajados 
manualmente. 
Hemos realizado análisis de tiempos de serie de la fosforilación de Stat1 y 
los niveles totales de Stat1 y Socs1 mediante ensayos de Luminex (Fig. 4) y los 
niveles de Stat1, IRF1 y SOCS1 mRNA tras la estimulación de IFN-beta 
mediante RT-PCR (Fig. 3). Entonces, comparamos los resultados experimentales 
con simulaciones de modelos matemáticos para evaluar la concordancia de las 
dinámicas en un nivel cualitativo 
dS=dt ¼ bs−λsS
dA=dt ¼ b expApn þ bdephApc
þ bAa− bphSA=kA1þ A=kA þ R=kIð Þq −λSTATA
dApc=dt ¼ bphSA=kA1þ A=kA þ R=kIð Þq −bimpApc  bdephApc
−λSTATApc
dApn=dt ¼ bimpApc−b expApn−λSTATApn
dr=dt ¼ br
Apn=kr
 n
1þ Apn=kr
 n −λrr
dR=dt ¼ bRr−λRR
df =dt ¼ bf
Apn=kf
 m
1þ Apn=kf
 m −λf f
dF=dt ¼ bF f −λFF
da=dt ¼ ba F=kFð Þ
u
1þ F=kFð Þu −λaaþ BSTAT
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Figura 3. Expresión génica de los niveles de Stat1, IRF1 y Socs1 tras la 
estimulación con IFN-beta y las correspondientes simulaciones del modelo ODE A-C) 
Las concentraciones de Stat 1, IRF1 y RNA de SOCS1 en lisados celulares fueron medidas 
mediante RT-PCR en las células Raw estimuladas con IFN-Beta (1000 unidades/ml) 
. Los experimentos descubrieron diversas características importantes de 
las dinámicas de señalización de Jak/Stat durante las ocho primeras horas 
después del tratamiento con IFN-beta. Por ejemplo, nuestros resultados 
mostraron la naturaleza oscilatoria de la activación de Stat1 (pStat1), con un 
rápido incremento de la concentración de cytosol pronto tras la estimulación 
(durante la primera hora), seguida por un segundo pico de concentración 
alrededor del minuto 200. Un objetivo crítico de la transcripción de Stat1 como 
Socs1 también mostró dos picos de expresión (correlacionados en el tiempo a los 
picos de pStat) alrededor de tras 90 y 250 mn tras la estimulación, mientras que 
otro objetivo importante, IRF1, exhibió una señal de plató en forma de campana 
de Bell. 
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Figura 4. Activación de la vía de señalización de IFN tipo I mediante IFN-beta 
en líneas celulares Raw y sus correspondientes simulaciones en el modelo ODE A-C) 
La concentración de proteínas pStat1, Stat1 y Socs1 en lisados celulares fue medida 
mediante Luminex, citometría de flujo o ELISA tras la estimulación con IFN-beta (1000 
unidades/ml). 
Capítulo 4. La translocación nuclear modela la cinética de la vía de 
señalización IFNbeta 
Realizamos simulaciones por ordenador usando diferentes condiciones y 
parámetros así como un análisis de sensibilidad y bifurcación del modelo 
desarrollado (fig. 5). El análisis de bifurcación indican la posible implicación de 
la translocación nuclear de pStat1 para la correcta actividad oscilatoria de las 
células una vez estimuladas in vitro con IFNbeta. Este descubrimiento nos llevó 
a la hipótesis de la alteración del proceso de translocación nuclear como 
respuesta a la terapia con IFNbeta. El análisis de bifurcación del modelo de la 
vía de señalización Stat1 identifica que la translocación al núcleo es un paso 
crítico.  
(A, C) La escala cromática representa el valor absoluto de la parte 
imaginaria de la ecuación de auto valores con parte máxima real, 
correspondiente al estado estable del sistema tras estimulación con IFN, para 
valores variantes de fosfo y defosforilación (bph y bdeph en el panel A), y ratios 
de importación/exportación nuclear (bexp y bimp en el panel B). Dos distintos 
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regímenes dinámicos pueden ser identificados con este análisis: el régimen 
oscilatorio amortiguado (en rojo) y el régimen sobre-amortiguado/no oscilatorio 
(en azul). 
 
 
Figura 5. Análisis de estabilidad de la solución en estado estable en espacios 
con parámetros de 2D  
 (B, D) Ejemplos de la evolución en el tiempo de pStat1 en ambos 
regímenes (amortiguado y sobre-amortiguado en las líneas rojas y azules, 
respectivamente), correspondientes a la posición de los parámetros de 
marcadores circulares para los dos diagramas mostrados en los paneles A y B, 
respectivamente. 
Para comprobar la hipótesis de que el proceso de translocación nuclear es 
crítico para la respuesta a la terapia con IFNbeta en pacientes con EM, 
evaluamos la translocación nuclear de Stat1 tras el tratamiento con IFNbeta en 
pacientes con EM usando la plataforma de imagen ImageStreamX. Ajustamos el 
protocolo estándar de la citometría de flujo usando PBMCs de los controles 
sanos. 
Obtuvimos PBMCs de controles y pacientes tratados con IFNbeta (n=4) en 
tiempos diferentes tras la inyección. Los resultados muestran diferencias 
significantes en el patrón de translocación nuclear entre individuos. 
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Capítulo 5. Modelo AKT-Foxo 
Para modelar la vía de señalización AKT/Sgk-Foxo3, hemos desarrollado 
un modelo ODE basado en conocimientos previos y datos experimentales. La 
característica principal de nuestro modelo es la exportación nuclear y la 
fosforilación de pFoxo3a mediante pAkt y pSgk tras la activación de la vía IGF1. 
La fosforilación de Foxo3a en los 3 principales fosfatos nos lleva a su 
desactivación y arresto en el citoplasma. Otras modificaciones post-
translacionales pueden llevar a su ubiquidad y su degradación (fig. 6). Los 
genes principales, regulados por Foxo3a TF, son Foxa2, las cyclinas D1, D2, D3, 
los inhibidores de quinasa dependiente de cyclina 1B y 1A, Bcl-6, Catalasa, el 
ligando Fas y otros. Nuestros modelos muestran la importancia del mecanismo 
de inhibición de Foxo3a para la reducción de ruido en el sistema. 
El gran interés en términos de tratamiento neuroprotectivo es la 
comunicación cruzada entre la vía de señalización PI3K y la activación de 
Foxo3a mediante ROS y su actividad apoptótica en condiciones de estrés 
oxidativo. La transportación nuclear es un parámetro crucial del sistema para 
mantener el equilibrio entre escenarios de supervivencia y apoptosis. 
 
Figura 6. El modelo de señalización Akt-Foxo3 y el transporte nuclear de Foxo3 
Discusión 
En la línea celular RAW, la expresión de los genes Socs1 y IRF1 cambia 
durante la primera respuesta al IFN, pero no existe expresión significante de 
algunos genes usados comúnmente como referencia (Mx1 y OAS1a). La 
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activación de la vía de señalización Jak-Stat mediante IFN-beta activa la 
fosforilación de Stat1, Stat2 y algunas otras proteínas. Estas proteínas activadas 
proceden principalmente de dos compuestos distintos: Stat1-Stat1 (compuesto 
AAF) y Stat1-Stat2-IRF9 (compuesto ISGF). Ambos compuestos activan 
numerosos genes en el núcleo, enlazándose a los elementos de regulación 
específicos en los promotores. El compuesto AAF se enlaza con los elementos 
GAS y el compuesto ISGF se enlaza con los elementos ISRE. Los genes 
contenedores de GAS (incluyendo Socs1 y IRF1) son responsables de la 
respuesta antibacteriana de las células y los genes contenedores de ISRE activan 
la respuesta antiviral de las células [15]. Basado en el background y nuestros 
resultados hemos hipotetizado que los macrófagos forman principalmente 
compuestos AAF que activan la ruta antibacterial (secuencias GAS), mientras 
que en las células T la situación es la opuesta, activando elementos ISFG3 y, por 
lo tanto, la respuesta antiviral. Por ejemplo, recientemente se mostró que la 
respuesta a IFN-beta difiere entre distintas células inmunes, y un análisis de los 
pacientes que no muestran respuesta a la terapia con IFN-beta indican una 
anulación diferencial de la vía de señalización IFN tipo I en los monocitos de 
estos pacientes [16]. 
La red de señalización de IFN afecta diferentes vías de compuestos, 
involucrando procesos como la diferenciación, la proliferación, la supervivencia 
y la muerte celular [17, 18], y además sirve como una terapia autoinmune [19]. 
IFN-beta es el tratamiento más común para la EM [20], y estudios genómicos 
previos han identificado ciertos genes pertenecientes a la vía de señalización 
IFN que están asociados con una falta de respuesta ante IFN-beta, sugiriendo 
que el background genético de ciertos individuos puede modular esta vía y, 
consecuentemente, la respuesta a la terapia, mediante perfiles transcripcionales 
específicos [22]. 
Nuestro estudio realza la importancia de identificar las dinámicas 
temporales de la concentración de ciertos elementos clave de la vía Jak-Stat, 
como la forma fosforilada de la proteína Stat1 y la expresión de los genes de 
transcripción estimulados con interferón como Socs1 y IRF1 durante las 
primeras 8 horas de la administración de IFN-beta. Catalogar estas dinámicas 
puede proveernos con biomarcadores moleculares tempranos que nos permitan 
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distinguir la falta de respuesta a la terapia con IFN-beta en ciertos pacientes con 
EM. 
Nuestro modelo también indica el rol crucial de la translocación nuclear 
de las moléculas de Stat1 para la correcta dinámica de la vía de señalización. Las 
alteraciones en estas características de translocación de Stat1 prevalecen sobre 
las tasas de fosforilación y defosforilación para determinar las dinámicas 
oscilatorias de la vía de señalización IFNbeta. En un pequeño grupo de 
pacientes con EM hemos mostrado que la tasa de translocación difiere 
substancialmente entre distintos individuos y puede determinar la diferencia de 
respuesta a la terapia o la progresión de la enfermedad. Los niveles de 
translocación de Stat1 pueden ser potenciales biomarcadores de la respuesta al 
tratamiento con IFNbeta y requieren más investigación. 
Otro ejemplo de la importancia de las características de transporte nuclear 
en la transducción de señales es el factor de transcripción Foxo3a. Foxo3a puede 
ser considerada como un regulador maestro de la vía PI3K-Akt, que determina 
la supervivencia o un escenario en el que la célula opta por la apoptosis. El 
modelo de señalización de Akt-Foxo3a es una herramienta interesante desde un 
punto de vista teorético y práctico.  
Desde el punto de vista teorético, la señalización de Akt-Foxo3a es un 
ejemplo de un grupo mayor de vías de señalización de transducción que tienen 
que ver con la toma de decisiones a nivel celular y que comparten un amplio 
número de pautas de comportamiento corrientes. La cinética de Akt-Foxo3a y 
su regulación y comunicación puede ser una tendencia común en toda la clase 
de vías de señalización. La razón de la estructura de inhibición y fosforilación 
nuclear es la resistencia al ruido de estos mecanismos de acción y múltiples 
posibilidades de ajuste y un cambio de comportamiento constante. 
Desde el punto de vista práctico, Foxo3a es cada vez más un blanco de 
investigación en la inmunología y la neurología [24, 25]. El nuevo fármaco 
neuroprotectivo prometedor, MS BN201, apunta a Sgk la quinasa de emisión de 
Foxo3a, modificando la actividad de Foxo3a. El entendimiento del 
comportamiento de Foxo3a en las células humanas en diferentes condiciones 
nos llevará a predecir los efectos de los nuevos tratamientos para la EM. 
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Conclusiones 
1. La población de células tiene la habilidad de coordinar y sincronizar su 
actividad en respuesta a la estimulación con IL-6. Esta habilidad es un atributo 
necesario de la señalización celular, que permite una correcta respuesta a los 
sistemas externos y provee una respuesta más robusta al entorno. 
2. Las células T y los macrófagos responden de manera diferente a IFNbeta, 
IFNgamma o a agentes infecciosos por las diferencias cualitativas en sus redes 
de señalización. Estas diferencias llevan a un amplio abanico de 
comportamientos de las células del sistema inmune en respuesta a distintos 
retos y al tratamiento con IFNbeta en enfermedades autoinmunes. 
3. La señalización de IFNbeta en los macrófagos toma la forma de dinámicas 
oscilatorias transitorias en la vía JAK-Stat, cuyas propiedades específicas de 
relajación determinan la longitud de la respuesta celular a la citoquina, lo cual 
tiene una implicación en el resultado de la respuesta inmune. 
4. La translocación nuclear de pStat1 modela las dinámicas del sistema de 
señalización JAK-Stat y lleva al cambio entre sistemas oscilatorios amortiguados 
y sobre-amortiguados. Individuos con distintas respuestas clínicas al 
tratamiento con IFNbeta mostraron diferencias en las dinámicas de traslocación 
nuclear de pStat1, convirtiéndolo en un biomarcador muy prometedor sobre la 
respuesta a esta terapia. 
5. La inhibición mediante fosforilación de pFoxo3a es un interruptor molecular, 
que constriñe la regulación de la actividad transcripcional de Foxo3a. El 
transporte nuclear de Foxo3a es un buffer cinético de la actividad de Foxo3 y 
mantiene el equilibrio entre los mecanismos de supervivencia celular y 
represión de tumor. Este mecanismo de cambio está controlado por la acción 
coordinada de Akt y Sgk en la vía de señalización PI3K. 
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Transient oscillatory dynamics of interferon beta
signaling in macrophages
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Abstract
Background: Interferon-beta (IFN-beta) activates the immune response through the type I IFN signaling pathway.
IFN-beta is important in the response to pathogen infections and is used as a therapy for Multiple Sclerosis. The
mechanisms of self-regulation and control of this pathway allow precise and environment-dependent response of
the cells in different conditions. Here we analyzed type I IFN signaling in response to IFN-beta in the macrophage
cell line RAW 264.7 by RT-PCR, ELISA and xMAP assays. The experimental results were interpreted by means of a
theoretical model of the pathway.
Results: Phosphorylation of the STAT1 protein (pSTAT1) and mRNA levels of the pSTAT1 inhibitor SOCS1 displayed
an attenuated oscillatory behavior after IFN-beta activation. In turn, mRNA levels of the interferon regulatory factor
IRF1 grew rapidly in the first 50–90 minutes after stimulation until a maximum value, and started to decrease slowly
around 200–250 min. The analysis of our kinetic model identified a significant role of the negative feedback from
SOCS1 in driving the observed damped oscillatory dynamics, and of the positive feedback from IRF1 in increasing
STAT1 basal levels. Our study shows that the system works as a biological damped relaxation oscillator based on a
phosphorylation-dephosphorylation network centered on STAT1. Moreover, a bifurcation analysis identified
translocation of pSTAT1 dimers to the nucleus as a critical step for regulating the dynamics of type I IFN pathway in
the first steps, which may be important in defining the response to IFN-beta therapy.
Conclusions: The immunomodulatory effect of IFN-beta signaling in macrophages takes the form of transient
oscillatory dynamics of the JAK-STAT pathway, whose specific relaxation properties determine the lifetime of the
cellular response to the cytokine.
Keywords: Type I interferon pathway, Interferon-beta, Ordinary differential equation, Oscillations, Multiple sclerosis,
Immunotherapy
Background
Type I interferons, such as interferon alfa and beta, are
cytokines that represent a first-line endogenous defense
mechanism in response to viruses and bacterial infec-
tions, are secreted by many cell types (e.g. lymphocytes,
macrophages and endothelial cells) and they are used as
a therapy in Multiple Sclerosis (MS).
The canonical type I interferon (IFN) pathway involves
different signaling cascades, one of which is the JAK/
STAT pathway. This pathway is composed by several
steps, which include receptor binding (IFNR1 and 2),
transformation of the latent transcription factor (a pro-
tein of the STAT family) into its active form by phos-
phorylation, nuclear migration of the transcription factor
(TF), binding of the TF to target promoters, and expres-
sion of their corresponding genes [1] (Figure 1). Previous
studies have shown that phosphorylated STAT1 forms
other TF complexes in response to type II interferons,
the most important of which is a STAT1-STAT1
homodimer, known as GAF, that binds to IFN Gamma-
activated sequence (GAS) elements [2].
The target genes of the IFN-beta pathway can be di-
vided into three categories according to the type of acti-
vating transcription factor: 1) the ISGF3 complex
activates genes containing an ISRE binding site in their
promoter (e.g. ISG15, Mx1, OAS1, IRF7). 2) The GAF
complex activates genes containing a GAS binding site
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in their promoter, such as SOCS1 and IRF1 [3,4]. 3) A
third class of STAT protein complexes activates other
canonical pathways that exhibit crosstalk with the JAK/
STAT pathway (such as PI3K, NFkB, MAPK) [5]. Re-
cently it was shown that different immune cell subtypes
respond differently to IFN-beta induction through acti-
vation of these different types of genes [6].
Different proteins regulate STAT1 phosphorylation.
Importantly, a negative feedback loop upon STAT1 acti-
vation coexists with a positive feedback mechanism.
First, the phosphorylation of STAT1 is inhibited by its
inhibitor SOCS1 [7]. The SOCS1 protein then inhibits
STAT1 phosphorylation at the kinase level. Besides this
negative loop based on SOCS1, STAT1 is a subject to
positive regulation via the TF IRF1, whose transcription
is induced by activated STAT1. IRF1 promotes the ex-
pression of the STAT1 gene at the transcriptional level.
Given the existence of these multiple feedback loops, a
mathematical modeling of the system would help provide
an understanding of the response to type I IFN-beta.
Here we analyzed the type-I IFN-beta signaling pathway
in macrophages, showing that the response of this path-
way to IFN-beta stimulation takes the form of transient
oscillations in STAT1 phosphorylation. We characterized
and identified the critical elements governing the transient
dynamics of IFN activation, and examined the influence of
this dynamical regime in the response to IFN-beta.
Dynamical models of IFN induction of the JAK/STAT
signaling pathway based on nonlinear ordinary differen-
tial equations, have been previously used to study the ef-
fect of IFN pre-treatment on the response of the
immune system to virus infection [8,9] and the robust-
ness of the pathway to noise and parameter fluctuations
[10], among other problems. Systems biology approaches
have also been applied to this pathway in order to exam-
ine its role in certain pathological mechanisms under-
lying the behavior of cancer cells [11], and its interaction
with other key signaling pathways [8,12]. Here we com-
bine our theoretical model with experimental observa-
tions. Our results show that a combination of positive
and negative feedback loops, together with the eventual
degradation of the IFN signal in the medium, leads to a
transient oscillatory response in several components of
the pathway. This behavior is consistent with previous
numerical results found in pure modeling studies [13],
and goes beyond previous observations that indicate a
simpler transient response [10,14,15]. We interpret the
transient oscillatory response of the pathway in terms of
the potential effectiveness of IFN-beta treatment in MS
patients.
Figure 1 The canonical type I and type II IFN signalling pathways. The plot represents the canonical IFN pathways and the cross-talk
between them, including the different pSTAT dimers formed after stimulation.
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Results
IFN-beta induces a transient oscillatory activation of the
STAT1 pathway
It is well known that microbial and viral infections in-
duce endogenous IFN-beta release by macrophages as
part of the immune cell system response. We could ob-
serve IFN-beta production accompanied with significant
increases in levels of phosphorylated STAT1 in the mur-
ine macrophage-like cell line RAW 264.7 stimulated
with lipopolysaccharide (LPS) endotoxin and also, with
viral fragments (poly(I:C)) (data not shown). In this
study we focused on STAT1 signaling by IFN-beta
stimulation in macrophages by challenging the RAW cell
line with increasing concentrations of mouse IFN-beta.
We observed that phosphorylated STAT1 levels in-
creased rapidly after IFN-beta induction (Figure 2A).
The increase was significant as soon as 2 min after
stimulation and reached a maximum at 10–15 min after
stimulation, followed by a decrease that correlates with a
substantial increase in the concentration of the SOCS1
protein (Figure 2C). A second, smaller peak was visible
at around 180 min, followed by a subsequent decrease
back to the baseline level after around 360 min. The
quick decrease of phosphorylated STAT1 levels is in
agreement with previous studies pointing to the activa-
tion of the negative feedback loop mediated by SOCS1
protein, which suppresses the phosphorylation of JAK1
and TYK2 proteins and prevents the formation of
STAT-dimers [16]. The total level of STAT1 protein, on
the other hand, is maintained practically constant until
around 200 min after stimulation, after which it starts
to increase slowly until the end of the experiments
(Figure 2B). STAT1 mRNA levels grew quickly and
continuously, starting sharply at around 75 min and
leveling off after 200 min (Figure 3A). This increase in
the mRNA level of STAT1, as soon as 1 hour after the
induction of response by IFN-beta, agrees with the in-
fluence of the positive feedback loop IRF1 – STAT1
Figure 2 Activation of type I IFN pathway by IFN-beta in Raw cell line and the corresponding simulations from the ODE model. A-C)
pSTAT1, STAT1 and SOCS1 protein concentration in cell lysates were measured by Luminex, Flow cytometry or ELISA after stimulation with IFN-
beta (1000 units/ml). The data was normalized to the maximum level. A) pSTAT1 protein concentration in the Raw cells stimulated with IFN-beta;
(B) Total STAT1 protein concentration in the Raw cells stimulated with IFN-beta; C) SOCS1 protein concentration in the Raw cells stimulated with
IFN-beta. We plot here one out of three independent experiments, which were performed in duplicates. D-F) Model simulation and sensitivity
analysis with ± 20% change for all parameters (shaded areas) (D: pSTAT1; E: STAT1; F: SOCS1).
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[17] and confirms the importance of this circuit for the
pathway dynamics.
To analyze the expression of regulatory genes of the
type I IFN pathway, we measured the levels of two
downstream STAT1 genes, SOCS1 (responsible of the
negative feedback) and IRF1 (mediator of the positive
feedback). We observed an oscillatory behavior of
SOCS1 mRNA during the first 360 minutes after stimu-
lation, with clear peaks at around 90 min and 250 min,
before returning to baseline levels (Figure 3C). On the
other hand, IRF1 shows different dynamics, with its con-
centration raising quickly between 30 and 120 min, then
reaching a plateau and decreasing more slowly after
250 min (Figure 3B). We also quantified the expression
levels of other downstream effector IFN-induced genes,
such as MX1 and OAS1b, but did not identify any acti-
vation of their transcription in the RAW 264.7 cell line
after IFN-beta stimulation (data not shown). These ob-
servations are in agreement with a differential signal
transduction mechanism in macrophages when com-
pared to canonical JAK-STAT pathway in lymphocytes
[4,18]. Our observations show that in the RAW 264.7
cell line the main activated genes were the ones con-
trolled by the STAT1-STAT1 homodimer (IRF1 and
SOCS1) and containing GAS elements in their promoter
region. These genes are mainly responsible for the anti-
microbial activity of the cells [19].
Modeling the oscillatory signaling of type I IFN pathway
In order to identify the critical elements of the signaling
pathway that are responsible for the transient oscillatory
behavior observed experimentally in macrophages upon
IFN-beta stimulation, we built an ODE model based in
biological knowledge and experimental data (Figure 4).
To minimize its complexity, we pursued the minimal
system explaining the experimental observations, instead
of a full descriptive system [14]. The model was not used
to reproduce sustained endogenous IFN activation after
viral infection, although it could be applied to that
scenario.
The first ingredient of our model is the binding of
IFN-beta to the receptor (with the concentration of acti-
vated receptor being represented by the variable S
below). The activated receptor induces phosphorylation
Figure 3 Gene expression levels of STAT1, IRF1 and SOCS1 after IFN-beta stimulation and the corresponding simulations from the ODE
model. A-C) STAT1, IRF1 and SOCS1 RNA protein concentration in cell lysates were measured by RT-PCR in the Raw cells stimulated with IFN-beta
(1000 units/ml); A) STAT1 RNA levels in the Raw cells stimulated with IFN-beta; B) IRF1 RNA levels in the Raw cells stimulated with IFN-beta; C) SOCS1
RNA levels in the Raw cells stimulated with IFN-beta. We plot here one out of three independent experiments, which were performed in duplicates.
D-F) Model simulation and sensitivity analysis with ± 20% change for all parameters (shaded areas) for STAT1 (D), IRF1 (E), and SOCS1 (F) RNA levels.
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of the STAT1 protein (represented by A). Phosphory-
lated STAT1 translocates from the cytoplasm (Apc) to
the nucleus (Apn) (Figure 4). In the nucleus, pSTAT1
complexes activate the transcription of SOCS1 and IRF1
genes. SOCS1 mRNA (r) is translated into SOCS1 pro-
tein (R), which inhibits further phosphorylation of
STAT1. IRF1 mRNA (f ) is translated to IRF1 protein (F),
which activates the transcription of the STAT1 gene
(with STAT1 mRNA being denoted by a). Each of the
species has a certain linear degradation rate. We also in-
troduced receptor internalization through an effective
degradation (or deactivation) term, consistent with the
literature [20]. With those ingredients, the model reads:
dS=dt ¼ bs−λsS
dA=dt ¼ b expApn þ bdephApc
þ bAa− bphSA=kA1þ A=kA þ R=kIð Þq −λSTATA
dApc=dt ¼ bphSA=kA1þ A=kA þ R=kIð Þq −bimpApc  bdephApc
−λSTATApc
dApn=dt ¼ bimpApc−b expApn−λSTATApn
dr=dt ¼ br
Apn=kr
 n
1þ Apn=kr
 n −λrr
dR=dt ¼ bRr−λRR
df =dt ¼ bf
Apn=kf
 m
1þ Apn=kf
 m −λf f
dF=dt ¼ bF f −λFF
da=dt ¼ ba F=kFð Þ
u
1þ F=kFð Þu −λaaþ BSTAT
The parameters correspond to transcription rates, in-
cluding basal transcription of STAT (ba, br, bf, BSTAT),
translation rates (bA, bR, bF), cooperativity indexes (Hill
coefficients, n, m, q, u), degradation rates (λi), receptor
activation (bS) and deactivation (λS) rates, phosphoryl-
ation and dephosphorylation rates (bph, bdeph), and
nucleo-cytoplasmic transport rates (bimp, bexp). We ad-
justed some of the parameters using published data
sources (Table 1), and the rest were estimated by manual
fit of the model dynamics to the experimental data
(Table 2) [21]. Initial conditions are listed in Table 3.
The model implements the SOCS1-mediated negative
feedback loop on pSTAT1 by means of a competitive in-
hibition term in the expression determining the phos-
phorylation rate of STAT1 in the equation for Apc, with
the parameter kI quantifying the half-maximal inhibition
threshold and the exponent q defining the sharpness of
the inhibition. Similarly, the positive feedback through
IRF1 is described by the transcription activation term of
STAT1 mRNA in the equation for a, with kF representing
the half-maximal activation threshold.
The right panels in Figures 2 and 3 show simulation
results corresponding to the experimental observations
presented in the left panels. For comparative purposes,
both the experimental and model variables were shown
in relative concentrations dividing by their maximum
value along the time series. We also performed a sensi-
tivity analysis by simulating changes of ±20% for every
model parameter, leading to deviations from the basal
curve falling within the shaded areas shown in Figures 2
and 3.
The model simulations reproduce the main features ob-
served experimentally, such as the first and very fast peak
of phosphorylated STAT1 shortly after IFN-beta stimula-
tion, and the second peak of smaller amplitude at around
200 min (Figure 2D). The concentration of total STAT1
protein is almost constant during the first 200 min, after
which the protein level increases slowly (Figure 2E), fol-
lowing the increased expression level of STAT1 mRNA,
which mRNA grows slowly starting at around 50 min after
stimulation (Figure 3D). In turn, SOCS1 mRNA levels
Figure 4 Mathematical model of type I IFN signaling pathway.
Graphical representation of the biological processes modeled.
Table 1 Parameter values obtained from the literature
Parameter Value Reference
bdeph 15 min half-life [36,37]
n 3 [38]
u 1 [39]
λr 2.82 hour half-life This work
λf 1.23 hour half-life [40]
A initial 105 molecules/cell [41]
S initial 700-900 receptors/cell [42]
λSTAT protein 24 hour half-life [43]
λF 30 min half-life [44]
f initial 1 molecule/cell [45]
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increase from the beginning, showing a first peak at
around 90 min and a second smaller peak following the
second peak of phosphorylated STAT1 at around 250 min
(Figure 3F), in agreement with the experiments. Again
similarly to the experiments, IRF1 mRNA levels show a
bell-shaped time course (Figure 3E), with an increase re-
sembling that of SOCS1 mRNA levels (Figure 3F) and
remaining high from around 90 min to 250 min, when
IRF1 mRNA levels decrease to half their maximum value
at around 350 min.
The model allows us to interpret the second peak ob-
served experimentally in pSTAT1 and SOCS1-mRNA
levels in terms of an underlying damped oscillatory dy-
namics. We now ask what are the mechanisms leading
to oscillations, on the one hand, and to damping, on the
other hand. A well-known gene circuit architecture that
leads to oscillatory behavior is a combination of positive
and negative feedback loops [22]. As mentioned above,
our model contains a negative feedback loop mediated
by SOCS1. We can examine in the model the effect of
not having this feedback by eliminating SOCS1 signaling
from the model. The results show that this negative
feedback is required for the oscillatory behavior to arise:
its absence leads to a transient plateau of high pSTAT1
levels during the first 4–5 h of IFN treatment (Figure 5B),
which contrasts with the relaxation oscillator behavior
obtained for our basal parameter values (Figure 5A),
which is a closer match to the experimental observations
(Figures 2–3). The model also contains a positive feed-
back loop mediated by IRF1. This loop, however, does
not appear to be crucial for the oscillatory behavior of
pSTAT1 (Figure 5C), and is only necessary to reproduce
the experimentally observed increase of STAT1 expres-
sion (Figure 3A D).
The combination of negative and positive feedbacks
discussed in the preceding paragraph would naturally
lead to sustained oscillatory behavior. The experimental
observations shown in Figures 2 and 3, however, reveal a
strong damping of the oscillations that lead to their sud-
den disappearance. This behavior is not consistent with
the standard damping undergone by nonlinear oscilla-
tions when they become unstable via a Hopf bifurcation,
in which case the damping is either slow close to the bi-
furcation, or the damped oscillations are too weak to
begin with far away from the bifurcation. A key distinct-
ive characteristic of our model is the fact that the exter-
nal input to which the system is subject (mediated by
the activated receptors represented by S in the model
above) decays monotonously due to receptor inactiva-
tion by internalization or degradation [20,23]. Assuming
Table 2 Parameters for type I IFN ODE model
Name Symbol Value Unity
Translation rate for STAT1 bA 65 min
-1
Receptor production rate bS 0 min
-1
Basal STAT1 RNA BSTAT1 0.0062 min
-1
Transcription rate for STAT1 ba 0.1 min
-1
Transcription rate for SOCS1 br 12.8 min
-1
Transcription rate for IRF1 bf 2.7 min
-1
Translation rate for IRF1 bF 1.0 · 10
1 min-1
Translation rate for SOCS1 bR 1.0 · 10
2 min-1
Phosphorylation STAT1 rate bph 1.3 · 10
3 min-1
Dephosphorylation STAT1 rate bdeph 0.036 min
-1
Import to the nucleus rate (pSTAT1) bimp 0.013 min
-1
Export from the nucleus rate (STAT1) bexp 0.048 min
-1
STAT1 phosphorylation activation (Hill’s
constant; half maximal activation)
kA 4680 molecules
Dissociation constant for the enzyme-
inhibitor by SOCS1 (Hill’s constant; half
maximal activation)
kI 82680 molecules
SOCS1 transcription activation by nuclear
pSTAT1 (Hill’s constant; half maximal
activation)
kr 23400 molecules
IRF1 transcriptional activation by pSTAT1 kf 7366 molecules
STAT1 transcriptional activation by IRF1 kF 1.3 · 10
5 molecules
Cooperativity of SOCS1 protein over
STAT1 dimers
q 4
Cooperativity of STAT1 on SOCS1 gene
promoter
n 3
Cooperativity of STAT1 on IRF1 gene
promoter
m 2
Cooperativity of IRF1 on STAT1 gene
promoter
u 1
Receptor internalization/degradation rate λS 0.0229 min-1
SOCS1 RNA degradation rate λr 0.0347 min-1
SOCS1 protein degradation rate λR 0.0231 min-1
IRF1 RNA degradation rate λf 0.0173 min-1
IRF1 protein degradation rate λF 0.0116 min-1
STAT1 RNA degradation rate λa 0.0058 min-1
STAT1 protein degradation rate λSTAT 0.0007 min-1
Table 3 Initial conditions for type I IFN model simulations
Name Symbol Value
Non-phosphorylated STAT1 A 1.0 · 105 molecules
IFN activation receptor S 1000 molecules
Phosphorylated nuclear STAT1 Apn 1 molecule
Phosphorylated cytoplasmic STAT1 Apc 10 molecules
STAT1 mRNA a 1 molecule
IRF1 mRNA f 1 molecule
SOCS1 mRNA r 1 molecule
IRF1 protein F 1 molecules
SOCS1 protein R 1 molecule
Pertsovskaya et al. BMC Systems Biology 2013, 7:59 Page 6 of 12
http://www.biomedcentral.com/1752-0509/7/59
  150
 
  
a linear decay, the external input decreases exponentially
(Figure 6A), taking the system quickly out of the oscil-
latory regime and thus leading to a strong damping of
the oscillations, as seen experimentally. Exploring sys-
tematically the dependence of the dynamics on the re-
ceptor level, we observed that as the initial levels of
activated receptor decrease (Figure 6A) the second peak of
both pSTAT1 (Figure 6B) and SOCS1 mRNA (Figure 6C)
levels diminish, with the SOCS1 expression peak dis-
appearing earlier than the pSTAT1 concentration peak.
Bifurcation analysis of the STAT1 pathway model
identifies translocation to the nucleus as a critical step
The temporal evolution of the phosphorylation of
STAT1 can be crucial for understanding the response to
IFN-beta therapy, and may provide an explanation of the
lack of response to this therapy in some cases [24]. In
particular, transient oscillatory dynamics could provide a
way for the STAT1 pathway to increase the duration
of its response to IFN-beta in a physiological manner
(i.e. without a period of sustained constant activation
as in Figure 5B). In order to establish the conditions
under which this transient dynamics exists, we ana-
lyzed the behavior of the system for combinations of
two-parameter pairs, distinguishing between the param-
eter values for which pSTAT dynamics is overdamped
(and thus non-oscillatory) and those for which the oscilla-
tions are underdamped (which corresponds to the experi-
mental situation reported above). We focused on the
phosphorylation and dephosphorylation rates (bph and
bdeph) and export and import rates (bexp and bimp). These
parameters represent crucial steps to regulate the nuclear
availability of transcription factors such as pSTAT dimers,
and thus also the expression of downstream genes.
In order to identify mathematically the two different
dynamical regimes mentioned above, we examined the
stability properties of the steady state of the ODE system
for a constant activated receptor level (S) equal to its
Figure 5 Type I IFN pathway model simulations during the first 8 hours after IFN-beta stimulation. (A) Model simulations showing
oscillations of total (nuclear plus cytoplasmic) pSTAT1 protein, SOCS1 mRNA expression (dashed line) and STAT1 mRNA expression (dotted line).
(B) Corresponding simulations where the SOCS1-mediated negative feedback is disrupted by assuming an infinite value of the repression
threshold kI. (C) Corresponding simulations not including the IRF1-mediated positive feedback, by assuming a zero value of the STAT1 activation
threshold kF (which leads to saturation of the corresponding Hill function, so that the dependence of a expression on F is removed).
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initial value. In that context, the underdamped/oscillatory
regime is characterized by a steady state that takes the
form of an unstable focus (i.e. the stability eigenvalue with
maximum real part has negative imaginary part), whereas
the steady state in the overdamped/non-oscillatory regime
is a node (the stability eigenvalue with maximum real part
has no imaginary component). In that way, by calculating
the imaginary part of the stability eigenvalue of the steady
state with maximum real part, we can identify the param-
eter regions in which the pathway exhibits a transient os-
cillatory response to IFN-beta. The result, for the
parameter space formed by the phosphorylation and de-
phosphorylation rates bph and bdeph, is shown in Figure 7A.
This figure shows, on the one hand, the prevalence of os-
cillations for a wide range of these parameters, and on the
other hand it tells us the conditions for which transient
oscillations exist. For instance, increasing sufficiently the
dephosphorylation rate can transform an oscillatory
regime into a non-oscillatory one, and reversely, by mak-
ing the phosphorylation rate large enough the system can
be made to exhibit transient oscillations. Figure 7B shows
examples of these two dynamical regimes for two specific
parameter sets within this phase diagram.
We also tested the influence of the import rate of
pSTAT1 molecules into the nucleus, and of the export
rate of STAT1 from the nucleus into the cytosol. By tun-
ing both parameters (bexp and bimp) simultaneously, we
observed again that the transient oscillatory regime is
prevalent in this system (Figure 7C). We found that the
oscillatory regime is associated with high nuclear import
rates in combination with high export rates. For high ex-
port rates but low import rates, the pathway exhibits an
overdamped (non-oscillatory) response, showing a
sustained plateau in the transient level of pSTAT1 (dis-
continuous blue line in Figure 7D). Conversely, for high
import rates and low export rates the response is also
Figure 6 Influence of activated receptor level on the transient oscillatory dynamics. (A) Time evolution of the activation level of type I IFN
receptors in the model (S) by stimulation with IFN-beta (added at t = 0) for different initial levels (in red, S = 500 molecules at t = 0). (B, C) pSTAT1
(B) and SOCS1 mRNA (C) dynamic responses for varying levels of initial receptor activation as in panel A (lower lines in B and C correspond to
lower lines in A).
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overdamped, but with a faster decay (continuous blue
line in Figure 7D).
Discussion
The aim of this work was to characterize the dynamics
of the key components of the type I IFN-beta signaling
pathway in macrophage RAW 264.7 cells. This system
robustly translates extracellular chemical signals through
cell membrane receptors, leading to phosphorylation of
the STAT transcription factors, which induce gene ex-
pression of multiple targets. JAK/STAT signaling directly
regulates the immune system response under viral or
bacterial infection, and is also important in auto-
immune diseases and cancer treatments. The IFN sig-
naling network affects different complex pathways,
involving processes such as differentiation, proliferation,
survival and cell death. Importantly, it is a canonical
pathway involved in first-line treatments of multiple scler-
osis as a main target of the IFN system [25] but, also, af-
fects different complex pathways, involving processes
such as differentiation, proliferation or survival and
cell death [26,27].
In this paper, we used a combination of experimental
approaches in order to obtain a quantitative picture of the
response of the JAK/STAT signaling pathway to IFN-beta
stimulation, and to identify the most relevant aspects of
its dynamics to be modeled with kinetic equations. Experi-
ments uncovered several important features of JAK/STAT
signaling dynamics during the first eight hours after treat-
ment with IFN-beta. For example, our results showed the
transient oscillatory nature of STAT1 activation (pSTAT1),
with a fast increase in cytosol concentration early after
stimulation (within the first hour), followed by a second-
ary concentration peak at around 200 min. A key STAT1
Figure 7 Stability analysis of the steady state solution in two 2D parameter spaces. (A, C) The color scale represents the absolute value of
the imaginary part of the stability eigenvalue with maximum real part, corresponding to the steady state of the system after IFN stimulation, for
varying phospho/ dephosphorylation rates (bph and bdeph, panel A), and nuclear export/import rates (bexp and bimp, panel B). Two distinct
dynamic regimes can be identified with this analysis: the damped oscillatory regime (shifted to red) and the overdamped/ non-oscillatory regime
(blue). (B, D) Examples of pSTAT1 time evolution in both regimes (damped and over-damped in red/blue lines, respectively) corresponding to
parameter position of circle markers for the two diagrams shown in panels A and B, respectively.
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transcription target such as SOCS1 also showed two peaks
of expression (correlated in time to the pSTAT peaks) at
around 90 min and 250 min after stimulation, whereas an-
other important target, namely IRF1, exhibited a more
bell-shaped plateau signal, respectively (Figures 2 and 3).
Our model simulations also exhibit a transient oscillatory
behavior in pSTAT1 concentration, and reveal that the os-
cillations require the presence of a negative feedback loop
on STAT1, mediated by its phosphorylation inhibitor
SOCS1. Previous mathematical models of the type I and
type II IFN pathways have suggested the possibility that
STAT1 pathway has an oscillatory behavior [9,13] and in-
dicated the importance of the SOCS1 negative feedback
[10,14,28,29]. Another factor that has been proposed to be
important in defining the response to IFN is the basal
level of receptors of the JAK/STAT pathway [30]. In our
model this aspect was also taken into account, showing
clear effects on the dynamics of the pathway response
(Figure 6). Going beyond previous models, our theoretical
results show that the physiological regime of the pathway’s
response to IFN-beta takes the form of damped oscilla-
tions that can be identified by means of a stability analysis
of the model’s steady state solution. This analysis shows
that processes such as the phosphorylation and dephos-
phorylation of pSTAT1, and the transport of STAT1 be-
tween the nuclear and cytosol compartments, can make
the pathway switch between underdamped and
overdamped oscillatory regimes [31].
Implications of the type I IFN signaling dynamics in
autoimmune diseases
IFN-beta is the most common treatment for MS [32],
exerting a pleiotropic immunomodulatory activity not
well understood [25]. IFN-beta treatment decreases acti-
vation, proliferation, cytokine release, and migratory
properties of activated T cells, diminishing their ability
to enter and damage the brain tissue. In spite of these
properties, up to 40% of patients do not respond to IFN-
beta therapy, which represents a significant health prob-
lem [24]. Previous genomic studies have identified certain
genes belonging to the IFN pathway that are associated
with a lack of response to IFN-beta, suggesting that the
genetic background of certain individuals may modulate
this pathway, and consequently the response to therapy,
by specific transcriptional profiles [33]. For example, it
was recently shown that the response to IFN-beta differs
between immune cells, and an analysis of non-responders
to IFN-beta therapy indicates an impairment of the type I
IFN pathway in the monocytes of those patients [6,34].
Our study indicates the importance of identifying the
temporal dynamics of the concentration of certain key
components of the JAK-STAT pathway, such as the
phosphorylated form of the STAT1 protein, and of the
expression of interferon-stimulated transcription genes
like SOCS1 and IRF1, within the first 8 hours of IFN-
beta administration. Cataloguing these dynamics could
provide us with early molecular biomarkers that allow us
to distinguish the lack of response to IFN-beta therapy
of certain MS patients.
Methods
Materials and reagents
Cells were obtained from ATCC library, mouse recom-
binant IFN-beta was purchased from Cell sciences, lipo-
polysaccharide from Escherichia coli and poly(I:C) salt
was purchased from Sigma-Albrich, lipofectamine 2000,
Hiperfect transfection agent were purchased from
QIAGEN, Taqman PCR master mix, VIC-dye GAPDH
endogenous control, IRF1, SOCS1, STAT1, STAT2,
MX1, OAS1a pre-designed FAM-dye assays were pur-
chased from Applied Biosystems, total STAT1 and
STAT1(pTyr701) antibodies and beads, cell detection kit
for xMAp assays were purchased from Merck Millipore
(Billerica). Alexa Flour 647 STAT1 (pTyr701) and PE
STAT1 N-terminal anti-Mouse antibodies and all buffers
for cytometry were purchased from BD biosciences.
APC-labelled IFNAR1 antibody was purchased from
Biolegend.
Cell culture and stimulation
Mouse leukemic monocyte macrophage cell line RAW
264.7 cell line was purchased from ATCC and maintained
in DMEM medium complemented with 10% fetal bovine
serum and 1% antibiotics at 37°C and 5% CO2. The cells
were passed every 2–3 days and maintained in 20-80%
surface coverage. One day before the stimulation the cells
were seeded in 12 well plates in concentration 1 × 106
cells/well. The cells were stimulated with 1000 units of re-
combinant mouse IFN-beta, 15 μg of LPS for different
times or 15 μg of poly (I:C) solution. At the end of stimu-
lation supernatants or cells were collected for further ana-
lysis. The same amount of PBS was added at the
corresponding time-points to the control samples.
RT-PCR
Cell lysates were prepared with QiaShredder columns
and total RNA was isolated using standard Qiagen
Rnaesy Mini kit protocol. Equal amount of total RNA
was added to each reverse transcription reaction tube
(High-Capacity cDNA Reverse Transcription Kit from
Applied Biosystems and cDNA was used for a second
step of RT-PCR. Results were analyzed using relative
2CTT method normalized to a GAPDH endogenous
control (VIC-dye primer-limited control from Applied
Biosystems) as described before [35]. All the qRT-PCR
experiments were performed in triplicates and repeated
three times independently.
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Western blot and quantification
Western blot (WB) was performed using polyclonal
rabbit anti-mouse pSTAT1 and STAT1 N-terminal anti-
bodies (Abcam) using standard WB protocol. Western
blot results were quantified using ImageJ software
(http://rsb.info.nih.gov/ij/index.html) using the method
of Luke Miller (http://www.lukemiller.org/journal/2007/
08/quantifying-western-blots-without.html)
ELISA and xMAP multiplexing assays
IFN-beta in culture supernatants and SOCS1 protein
concentration in cell lysates were measured by standard
sandwich ELISA with anti-mouse SOCS1 antibodies
(Abcam). IRF1 protein concentration in cell lysates was
measured by in-cell ELISA using the kit (Thermo Scien-
tific) STAT1 total protein and phosphorylated state
(Tyr701) concentrations (nuclear and cytoplasmic to-
gether) were measured using xMAP assays and read in
Luminex 201 platform using standard vacuum separ-
ation protocol (Millipore). xMAP experiments were re-
peated twice.
Flow cytometry
Cells for flow cytometry were stimulated with 1,000 μn/ml
of IFN-beta as stated before and fixed immediately after
stimulation. IFNAR1 receptor on the surface of the RAW
264.7 cells was marked using APC-labelled anti-IFNAR anti-
body. The mean fluorescent intensity was calculated using
FlowJo software. For STAT1 staining cells were fixed imme-
diately after stimulation in order to preserve phosphoryl-
ation and then permeabilized using Perm III buffer (BD
biosciences). Samples were stained simultaneously with anti-
STAT1 (pTyr701) and anti-STAT1 total (N-terminus) anti-
bodies. The mean fluorescent intensity, the percent of
staining-positive cells, the medians and the standard devi-
ation were calculated using FlowJo software and the raw
single-cell data were extracted to plot the histograms and
further analysis.
Mathematical modeling
The model and simulations were run in MATLAB using the
ODE15s solver (Matlab codes are provided in the Additional
files 1, 2 and 3). The stability analysis of the dynamical sys-
tem was performed with custom-made Matlab codes.
Availability of supporting data
The model is available as a matlab script in the supporting
materials. The raw experimental data are available from
the authors upon request.
Additional files
Additional file 1: Type I IFN pathway ODE model equations.
Additional file 2: Type I IFN pathway ODE model as Matlab file.
Additional file 3: Integration and solutions of the Type I IFN
pathway ODE model as Matlab file.
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